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The field of 3D culture models of disease has started to move towards systems 
that aim to recapitulate the complexity of human tissues. However, despite 
recent improvements, current 3D systems remain overly simplistic, lacking the 
biophysical characteristics and diverse structures found in most organs. 
In this project, the cellular behaviour of breast cancer and their responsiveness 
to chemotherapeutic agents were evaluated under different 3D cell culture 
conditions. MDA-MB231 and SKBR3 cells were prepared as spheroids using 
ultra-low attachment plates and as 'artificial cancer masses' (ACM) by 
embedding cells in a dense collagen type-I. The ACMs were maintained under 
flow (150 µL/min) and flow/pressure (550 μL/min, ~19 mmHg) conditions. A 
significant reduction in cell viability was observed when cancer cells were 
grown as ACM compared to 2D culture. Cell viability also declined significantly 
when ACMs were maintained in flow/pressure condition compared to static 
condition. Similarly, an increase in the expression levels of markers of EMT 
was observed when cells were cultured as ACM. However, compared to static 
3D incorporation of flow and pressure was associated with decreased 
expression levels of vimentin, HIF1-α, whilst MMP14 expression increased 
and snail remained unchanged. HER2 levels were increased in SKBR3 when 
the cells were cultured under flow/pressure (1.5 fold) compared to static 
condition. Overall, cells cultured as ACMs exhibited reduced responsiveness 
to doxorubicin compared to those grown in the conventional 2D culture. A 
decrease sensitivity was also observed in 3D/flow/pressure and 3D/flow 
compared to 3D/static condition.   
The results obtained in this study show that cancer cell behaviour and their 
response to therapeutic agents are affected by different microenvironments. 
Therefore, a new generation of 3D in vitro models need to be developed as 
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 Breast Cancer Epidemiology 
 
Breast cancer is amongst the most common cancers in women and the 
incidence is increasing globally.  There were an estimated 1.4 million new 
cases diagnosed worldwide in 2008 and nearly 459,000 breast cancer related 
deaths worldwide (DeSantis et al., 2014). In 2012, the GLOBOCAN project 
released statistics showing that 1.7 million women were diagnosed and 
522,000 succumbed to breast cancer. According to the American Cancer 
Society, one in eight women in the United States will be diagnosed with breast 
cancer in her lifetime (Hortobagyi et al., 2005). Furthermore, it has been 
estimated that the annual worldwide incidence of female breast cancer will rise 
to approximately 3.2 million new cases by 2050 (Ma and Jemal, 2013). Even 
though breast cancer incidence is rising worldwide, the figures for developed 
countries are higher than those for less developed countries. Conversely, the 
mortality rate is higher in less developed countries partly due to the lack of 
screening tests and consequential late stage at diagnosis. These trends 
demonstrate that breast cancer incidence and its effect on society is a 
worldwide health problem and new diagnostic and therapeutic measures are 
needed. 
 
  Breast cancer subtypes 
 
In any tumour stratification system, important considerations include the origin 
and histology of the tumour, in breast cancer this includes ductal or lobular 
cancer and whether the primary tumour is in situ or invasive and the extent of 
any local-regional or distant metastases. In the clinical setting, breast tumours 
are initially classed into three main subtypes: tumours expressing oestrogen 
receptor (ER α/β) and/or progesterone receptor (PR), generally referred to as 
hormone receptor–positive [HR-positive] tumours, Erb-B2 amplified also 
known as human epidermal growth factor receptor 2–amplified [human 
epidermal growth factor-2; HER2-amplified] breast cancer, and a group which 
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lack expression of the ERs, PR and HER2 called triple-negative breast cancer 
(TNBC). Recently, based on the gene expression profile of breast cancer 
tissues, new molecular classifications have been established: luminal A, 
luminal B, basal-like, HER2-enriched and unclassified or normal breast 
(Sotiriou et al., 2003, Prat and Perou, 2011).  It has been shown that these 
different subtypes are associated with different prognostic features such as 
the frequency of ER/PR/HER2 expression, histological grade, p53 mutation 
status and varying levels of genes of proliferation (Eroles et al., 2012). In 
addition, stratification of breast cancer to different subtypes has provided a 
predictive tool for the response to different therapies (Siow et al., 2018). A 
number of new prognostic approaches using gene profiling platforms have 
been developed recently. Among these analyses, Oncotype DX and 
Mammaprint are the most extensively cited and are tools that are being trialled 
for determining which subgroups of breast cancer patients will respond to 
hormonal and/or chemotherapy (Van De Vijver et al., 2002, Kittaneh et al., 
2013) with the aim of better targeting the treatments. For example, a recent 
report of the Oncotype DX system with 10,273 early-stage hormone receptor-
positive, HER2-negative and axillary node-negative breast cancer patients, 
with 7.5 years follow-up, showed that an Oncotype DX recurrence score of 11-
25 indicated patients for whom the addition of chemotherapy did not improve 
disease-free survival; in the presence of hormone therapy. The study also 
revealed a subgroup of patients who did not benefit from post-operative 
chemotherapy (Oncology, 2018) illustrating the potential for gene-expression 









1.2.1 Luminal tumours                  
 
Luminal-like tumours, the most prevalent breast cancer subtype, are positive 
for hormone receptors in immunohistochemistry (IHC) assessments. The gene 
expression patterns of these tumours include expression of luminal breast 
epithelial cell cytokeratins 8/18, ER and genes associated with ER activation 
such as LIV1 and CCND1 and similar to the luminal epithelial cells of normal 
healthy breast tissue.  Luminal tumours are themselves divided into two 
subtypes: luminal A and luminal B, both subtypes represent ER+, PR+, HER2- 
breast cancer in the basic clinical assessment. However, some luminal B 
tumours have also been reported to be HER2+ (Cheang et al., 2009). A key 
feature of luminal B tumours is increased expression levels of genes 
associated with cell proliferation (including MKI67) and lower expression levels 
of ER-related genes compared to luminal A. In general, the luminal breast 
cancer subtype has a good prognosis compared to the other subtypes. 
Comparing the two subtypes, luminal B carries significantly worse prognosis 
than the luminal A (Sorlie et al., 2003). Endocrine therapy has been the 
approved therapeutic strategy for the treatment of both luminal A and B 
tumours. However, for the luminal B subtype which has higher cell proliferative 
activity, a combination of hormone therapy and chemotherapy has been 
shown to be more beneficial (Dai et al., 2015).  
1.2.2 HER2 over-expressing breast tumours 
 
HER2 amplification occurs in approximately 20% of invasive breast cancers 
and is associated with a poorer prognosis and a reduced overall survival. 
HER2 has been a target for breast cancer therapy (Sjögren et al., 1998) with 
Trastuzumab (Herceptin), a humanised recombinant antibody which binds to 
extracellular domain of HER2, having been shown to benefit HER2+ breast 
cancer patients in combination with chemotherapy (Vogel et al., 2002). Despite 
all the benefits of Trastuzumab, many HER2 overexpressing breast tumours 
do not respond to this therapy (clinical benefit rate: 48%) when used as a 
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single agent, and both acquired and de novo resistance has been identified 
(Vogel et al., 2002). Lapatinib is a dual tyrosine kinase inhibitor that targets 
both HER2 and HER1 (EGFR) in breast cancer (Xia and Powell, 2002) and 
Pertuzumab is a monoclonal antibody that blocks dimerisation of HER2 with 
other HER family members via binding to the dimerisation domain (domain II) 
of the HER2 extracellular domain which is different to the binding site of 
Trastuzumab in domain IV (Franklin et al., 2004). Several clinical studies have 
suggested that a combination of Trastuzumab with either Pertuzumab and/or 
Lapatinib might be a valuable choice to avoid insufficient sensitivity or 
resistance to Trastuzumab (MacFarlane and Gelmon, 2011). In addition to 
these therapeutic strategies, the combination of Trastuzumab with 
chemotherapeutic agents enhances overall survival and reduces the risk of 
recurrence and this is considered the gold standard of care for patients with 
HER2 amplified breast carcinomas (Hudis, 2007). 
 
1.2.3 Triple negative breast cancer subtype 
 
Triple negative breast cancer (TNBC) refers to breast cancers exhibiting low 
levels of ER, PR and HER2. Epidemiological studies have shown that 
approximately 20 percent of all breast cancer patients are diagnosed with 
TNBC worldwide, accounting for approximately 200,000 new cases diagnosed 
each year (Swain, 2008). The TNBC subtype is more common in women of 
African descent compared to Caucasians and is also more common in 
premenopausal women under 40 years of age (Trivers et al., 2009). Based on 
gene-expression profile studies, TNBC maybe stratified to six subtypes: basal-
like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal stem cell-like (MSCL) and luminal androgen receptor (LAR) 
(Lehmann et al., 2011). In most of the literature, the basal-like subtype is 
identical to TNBC. Basal-like breast tumours express markers for basal-type 
cells and are defined as ER/PR/HER2 negative, CK5/6 positive, and/or 
positive for EGFR. Breast cancers that are positive for basal cell markers have 
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been shown to be associated with a poorer prognosis compared to the other 
TNBC subtypes. However, when treated with adjuvant chemotherapy, patients 
with basal like breast cancers had improved disease free survival compared 
to TNBC as a whole (Choi et al., 2010). 
To date no targeted therapy for patients with TNBC has been any approved 
and chemotherapy remains the main treatment for this type of breast cancer. 
However recent clinical trials have shown promising results using 
immunotherapeutic methods to target tumour cells that evade the immune 
system (García-Teijido et al., 2016). For instance, in a phase I clinical trial with 
metastatic TNBC tumours with positive programmed cell death protein 1 ligand 
(PD-L1), Pembrolizumab, a monoclonal anti PD-1 antibody was used as a 
check-point inhibitor to inhibit lymphocyte deactivation. The initial overall 
responses of 18.5% have been reported in heavily pre-treated TNBC (Nanda, 
2014). 
 
 Breast cancer hallmarks, biomarkers and subtypes 
 
Breast cancer has been described as the uncontrollable growth of epithelial 
cells of the breast tissue (Russo et al., 2000). Over the last three decades, 
scientists have focussed on the classification of breast cancer based on 
different traits and, accordingly, breast cancer is no longer considered a single 
disease in terms of diagnosis and treatment. Indeed, breast cancer is now 
recognised to be a highly heterogeneous disease. To understand this 
heterogeneity, scientists have applied many theories to describe breast cancer 
development; including the cancer stem cell and the clonal evolution 
hypotheses. Different breast tumour subtypes are associated with different risk 
factors, histopathological traits, outcome and response to systemic therapies 
(Dai et al., 2016). 
In 2000 Hanahan and Weinberg described six hallmarks of cancer and in 2011 
expanded these to include ‘genome instability and mutations’ and ‘tumour-
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promoting inflammation’ (Hanahan and Weinberg, 2011). These hallmarks of 
cancer, specifically those related to the aims of this project, will be explained 
in the following sections.  
 
1.3.1 Genome instability and gene mutation 
 
The preservation of the genome and ensuring genomic stability is vital for 
cellular integrity, to avoid mistakes arising from endogenous sources of DNA 
damage. These damages occur through DNA replication, recombination and 
through reactive oxygen species (ROS) produced during cellular metabolism. 
Exogenous genotoxic agents including ultraviolet light, ionizing radiation or 
DNA damaging chemicals can also generate genome instability. Cells activate 
pathways in response to these potentially deleterious events. For example, 
they undergo cell cycle arrest to repair acquired damage and stimulate DNA 
repair pathways, or if the damage is not repairable, mechanisms are activated 
to induce programmed cell death (apoptosis). Damage/failure of these 
mechanisms results in both the initiation and the progression of cancer 
(Nowell, 1976). Genome instability refers to either small structural changes 
including increased incidences of point mutation, microsatellite instability or 
substantial structural changes resulting from chromosome instability 
(Charames and Bapat, 2003). Various guardian genes and molecular 
pathways are involved in the maintenance of genomic instability including 
proteins involved in DNA damage check points (e.g. p53 and ataxia 
telangiectasia-mutated, ATM, protein), as well as several DNA repair 
pathways including nucleotide excision repair (NER), base excision repair 
(BER), mismatch repair (MMR) and DNA double strand break repair (DSBR) 
(Charames and Bapat, 2003). Errors that occur during cell division are also 
known sources of chromosome instability and a number of mechanisms, 
known as mitotic checkpoints, serve to monitor the correctness of each stage 
of the cell cycle before the instigation of nuclear division (Charames and 
Bapat, 2003).  
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Amongst all proteins involved in maintaining gene integrity, TP53 has been 
most studied (El-Deiry, 1998).  A multitude of functions have been attributed 
to p53 and these have led to the term 'gatekeeper of the genome' in response 
to the intracellular role of the TP53 protein during cellular stress such as 
hypoxia, oncogene activation and DNA damage. Dysfunction in p53/TP53 
leads to changes in gene stability and integrity and has been reported to result 
in uncontrolled proliferative activity of cancer cells. Mutated p53 has been 
reported in approximately 25 to 30% of breast tumours and has emerged as 
an important independent prognostic marker (Børresen‐Dale, 2003). It has 
also been observed that mutations in p53 may confer drug resistance, for 
example, to the hormone therapy Tamoxifen.  Various studies have also 
shown that sensitivity of ER-TP53- tumours to chemotherapy is decreased 
compared to ER-TP53+ tumours (Børresen‐Dale, 2003, Lønning et al., 2007). 
Taken together, the evidence suggests that ‘genome instability and mutations’ 
in breast tumour is associated with resistance to conventional treatment 
strategies. 
1.3.2 Supporting proliferative signalling 
 
Oncogenes and tumour suppressor genes are the main regulators of cell 
growth, proliferation, differentiation and cell death. Mutated oncogenes or 
tumour suppressor genes play a crucial role in both the initiation and the 
development of tumours (Ghourab, 1992). The most well-described hormonal 
and growth receptors that operate cell growth signalling in breast cancer 
include ER, PR and HER2. These receptors are used as differential markers 
for the routine subtyping of breast cancer tumours using established IHC 
staining protocols in pathology laboratories worldwide (Spitale et al., 2008). 
ERs are nuclear hormone receptors (NHRs) belonging to a large nuclear 
receptor family and primarily act as transcription factors. ERα is the major ER 
subtype in the mammary epithelium and is the isoform detected by antibodies 
used during diagnostic procedures. Approximately 75% of all breast cancer 
patients are diagnosed with ERα positive breast cancer (Anderson et al., 
2002). In comparison with ER- tumours, ER+ tumours show greater 
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differentiation, are less aggressive, and are associated with better post-
surgical outcomes (Dunnwald et al., 2007). Endocrine therapy using 
Tamoxifen, a selective ER modulator, and aromatase inhibitors, which ablate 
peripheral estrogen synthesis, has been shown to substantially improve 
disease-free survival after breast cancer. Although the role of PR in the 
classification of breast tumours is still questioned, assessment of PR status in 
such tumours has shown to be helpful for predicting patient benefit from 
endocrine therapy (Rakha et al., 2007). Endocrine treatment, particularly for 
metastatic tumours, has shown to be less effective for ER+PR- tumours than 
ER+PR+ tumours.   
Another important family of receptors, upregulated in breast and also other 
cancers, is the HER family of receptor tyrosine kinases. These receptors span 
the cell membrane and on binding to extracellular growth factor ligands 
activate intracellular signal transduction pathways, enabling cells to respond 
to their environment correctly. This family of protein receptors comprises four 
members: Erb-B1/EGFR/HER1, Erb-B2/HER2/Neu, Erb-B3/HER3 and Erb-
B4/HER4 (Nuciforo et al., 2015). 
In addition to ER, PR and HER2, androgen receptor (AR) has also been 
assessed as a means of classification of different breast cancer subtypes. AR 
is another member of the family of nuclear steroid hormone receptors and is a 
transcription factor playing crucial roles in various signalling pathways. 
Following binding of androgens, including testosterone and 
dihydrotestosterone, AR translocates to the nucleus where it binds to promoter 
regions of target genes and activates transcription (Zhu et al., 1999). AR is 
expressed in 90% of ER positive and 55% of ER negative breast tumours 
(Ogawa et al., 2008, Hu et al., 2011) and is a potential marker for breast cancer 
prognostication and also a prospective therapeutic target.  
In combination with hormonal receptors, proliferation markers especially Ki67 
have been used to predict the outcome of breast cancer treatment. Ki67, 
encoded by the MKI67 gene, is present mainly in dividing cells and functions 
to stabilise the mitotic spindle by recruiting Hklp2 (kinesin-12) to mitotic 
chromosomes (Vanneste et al., 2009). In another classification of 
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ER+PR+HER-, Ki67 positivity was shown to relate to poorer outcome 
regardless of the choice of systemic therapy (Cheang et al., 2009). Expression 
levels of topoisomerase II alpha (TOP2A) which plays a crucial role in the 
relaxation of supercoiled DNA is also associated with Ki67 levels (Mueller et 
al., 2004). HER2-amplified breast tumours with aberrations in the TOP2A 
biomarker have been reported to be more responsive to anthracycline-based 
chemotherapy (Ejlertsen et al., 2009). Overexpression of other proliferation 
markers including cell cycle genes has been reported as an indicator of poor 
clinical outcome in ER+PR+ tumours (Loi et al., 2007). 
1.3.3 Invasion and metastasis 
 
Metastasis occurs when primary tumour cells migrate and invade into 
surrounding blood or lymphatic vessels through the process termed 
intravasation. Through this process some of tumour cells circulate via the 
vasculature, evading immune recognition, and colonise distant organs through 
the process known as extravasation (Hunter et al., 2008). Many of the cellular 
and molecular traits that are key to this process have been documented. 
Amongst all steps of the molecular and cellular cascade involved in 
metastasis, depicted in Figure 1, two initial steps are the focus of this project 
and will be described in further detail below. 
1.3.4 Detachment of cancer cells from the primary tumour 
 
Primary epithelial cancer cells are attached to each other and also to 
extracellular matrix (ECM) components through cell adhesion molecules 
(CAMs). Cadherins, integrins and carcinoembryonic antigen-related cell 
adhesion molecules (CEACAM) constitute the main groups of CAMs of breast 
tumours. Integrins are heterodimeric transmembrane receptors with a role in 
cell-cell and cell-matrix interactions, they also regulate signalling pathways 
involved in proliferation, migration and survival (Giancotti and Ruoslahti, 
1999). Cell-cell interactions and integrin-mediated attachment to the ECM are 
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crucial factors for proliferation and growth of mammary epithelial cells without 
which cells would succumb to a form of apoptosis known as anoikis. Integrin 
receptors are heterodimers, consisting of two subunits: α and β which 
assemble noncovalently. In mammals, 24 types of integrin have been reported 
as a result of assembly of 18 α subunits and 8 β subunits (Campbell and 
Humphries, 2011). Integrins of the breast epithelia act as sensors linking ECM 
ligands with the intracellular actin cytoskeleton and triggering kinases in the 
cell.   
At least eight integrin receptors have been described as receptors for different 
molecules of ECM of the mammary gland. α1β1, and α2β1 are collagen 
receptors, α3β1, α6β1, and α6β4 are laminin receptors and α5β1, αvβ1, and 
αvβ3 recognise RGD domains of, for example, fibronectin and vitronectin. 
Integrin receptors can transduce mechanical signals from the ECM to 
intracellular cytoskeletal proteins for example actin, or in the case of β4 
integrin, intermediate filament (Lambert et al., 2012). These receptors also 
transmit biochemical signals through tyrosine kinases such as the focal 
adhesion kinase (FAK) and/or Src. Integrin receptors and growth factor 
receptors such as HER2 interact physically and cooperate with each other to 
activate tyrosine kinase and MAP kinase pathways. In breast cancer, integrins 
are the key modulator of tumour initiation (Lambert et al., 2012). Deletion of 
β1 integrin in a transgenic mouse model of breast cancer was shown to 
impede tumourigenesis (White et al., 2004). In a similar study, loss of the 
cytoplasmic domain of β4 integrin in an HER2 overexpressing mouse model 
increased latency and decreased aggressiveness of ErbB2-induced tumours 
(Guo et al., 2006).   
At the onset of the metastatic process, cancer cells lose their adherence to 
neighbouring cells in focussed areas of the cells known as adherens junctions, 
this process is predominantly mediated by alterations in the expression levels 
of the cadherin family of proteins. A molecular signature of cadherins, notably: 
E-cadherin (-), N-cadherin (+), cadherin-11 (+), has been shown to be 
associated with epithelial mesenchymal transition (EMT, section 1.3.5) a 
phenomenon through which cancer cells gain a mesenchymal phenotype and 




































































































































































































































































































































































































































































































1.3.5 Epithelial mesenchymal transition (EMT) 
 
EMT is a phenomenon through which epithelial cells lose their adherent traits 
and tight junctions and gain a mesenchymal phenotype, this process results 
in cells that are able to migrate over distances; Figure 2. Three main types of 
EMT have been described; type 1: biological events that occur during embryo 
formation, gastrulation and neural crest migration; type 2: wound healing, 
tissue regeneration and organ fibrosis, and, type 3: cancer metastasis (Kalluri 
and Weinberg, 2009).The role of EMT in breast cancer has been investigated 
via in vitro and in vivo studies and, taken together, the data suggest that breast 
cancer cells that undergo EMT exhibit a basal-like phenotype (Sarrió et al., 
2008). Several molecular changes have been observed for each type of EMT, 
some of the changes are common to all types of EMT whilst some are specific 
to only one type, and these provide a variety of biomarkers enabling studies 
of EMT. In the following section biomarkers associated with EMT are 
described in particular those relevant to breast cancer.  
 
1.3.5.1 Cell-membrane markers of EMT 
 
The cadherin superfamily consists of a group of eight transmembrane proteins 
contributing to calcium-dependent homophilic and heterophilic cell-to-cell 
adhesion; cadherins have important roles in the maintainance of cell polarity 
and are involved in cell motility. Cadherins have been reported to be present 
in a range of tissues and are classified into three types according to their 
structural characteristics. Type-I includes epithelial (E-cadherin), neural (N-
cadherin), placental (P-cadherin), and retinal (R-cadherin). Type-II include 
cadherin-11 (OB-cadherin) and vascular-endothelial cadherin (VE-cadherin); 
they share the same intracellular domain as type-I cadherins but differ in terms 
of a motif in the extracellular domain. Type-III or ‘atypical cadherins’ include 
cadherin-13 and cadherin-15; they lack the transmembrane domain identified 
in type-I and II cadherins. So far, evidence suggests that cadherin-13 and 
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cadherin-15 may be defined/considered as tumour suppressor genes. In vivo 
studies with murine tumour models have shown cadherin-13 to be 
downregulated in all cell types except endothelial cells (Hebbard et al., 2008). 
Moreover, cadherin-13 expression is repressed in breast cancer cell lines as 
well as primary breast cancers due to methylation of the promotor (Toyooka 
et al., 2001). In contrast, cadherin-13 expression is increased in the endothelial 
cells in breast cancer (Takeuchi et al., 1999). Loss of expression of E-cadherin 
occurs during all three types of EMT and is considered a hallmark of EMT. In 
addition to reduced gene expression levels, the loss of function at the protein 
level has also been associated with promotion of EMT (Okazaki et al., 1994, 
Huber et al., 2005). Expression levels of E-cadherin are decreased in breast, 
ovarian, gastric, thyroid and colorectal cancers (Sommers et al., 1989).  
Upregulation of N-cadherin normally occurs in cells with a mesenchymal 
phenotype including kidney and brain during development, and in fibroblasts 
and cancer cells. The upregulation of N-cadherin is accompanied by 
downregulation of epithelial related cadherins including E-cadherin. In recent 
studies ‘cadherin switching’ has been used as a marker to monitor EMT.  In 
addition, a switch from E-cadherin to cadherin-11 has been observed in type 
2 EMT accompanying tissue fibrosis. Cadherin-11, is mainly expressed in 
osteoblasts and to a very low extent in brain, lung and testicular tissue 
(Okazaki et al., 1994). Pohlodek et al have reported that cadherin-11 gene is 
overexpressed in the samples of invasive breast cancer. In another study led 
by Huang, cadherin-11 expression in prostate cancer cells was associated 
with increased invasion and migration as well as interaction with osteoblasts 
(Huang et al., 2010). Intracardial injection of cadherin-11 expressing prostate 
cancer cells in a murine model resulted in an increased rate of bone 
colonisation compared to injection of cadherin-11-knockdown prostate cancer 
cells (Chu et al., 2008).  Similarly, when renal  carcinoma cells were implanted 
into SCID mice, cadherin-11 levels on the surface of cells derived from bone 
metastases was increased compared to the cells derived from other sites of 
metastasis (Satcher et al., 2014). Highly metastatic prostate cancer PC3-mm2 
cells showed a significant reduction in bone metastasis following the 
downregulation of cadherin-11 using specific short hairpin RNA (Chu et al., 
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2008). These findings have led researchers to develop an antibody against the 
extracellular domain of cadherin 11, with the aim of reducing cancer 
metastasis to bone (Lee et al., 2013). In a study, Lee et al. produced a panel 
of 21 antibodies against extracellular domain of cadherin-11 among which two 
showed promising results for the recognition of an adhesion motif in the 
extracellular domain of cadherin-11. Their further investigations in which 
animals were treated with one of those antibodies resulted in a decrease in 
the metastasis of prostate cancer cells to bone (Lee et al., 2013). In another 
study by Pishvaian et al (1999), cadherin-11 mRNA and protein levels were 
reported to be elevated in several invasive breast cancer cell lines including 
MDA-MB-231, BT549 and HS578T cells. However, there are contradictory 
data with regards to cadherin-11 expression levels in various cancer studies.  
In 2012, Li et al. reported cadherin-11 status showing that the cadherin-11 
promoter is methylated and inactivated in cancer cell lines including 
nasopharyngeal, esophageal, gastric, hepatocellular, colorectal, breast and 
cervix. A tumour suppressor function was suggested for cadherin-11 via 
induction of apoptosis and inhibition of cell migration and invasion through 
Wnt/ β-catenin and AKT/ Rho A signalling.  
 
1.3.5.2 Cytoskeletal markers of EMT 
 
The cytoskeletal proteins most studied in relation to EMT are fibroblast-specific 
protein 1 (FSP1), α-smooth muscle actin (α-SMA), vimentin and β-catenin.  
FSP1 is a member of the Ca+2-binding S100 protein family and is a fibroblast 
protein detecting both type 2 and type 3 EMT. Increased expression-levels of 
FSP1 have been observed as part of the type 3 EMT process of metastatic 
cells in different cancer models (Xue et al., 2003). α-SMA is a member of the 
actin family of cytoskeletal proteins. Myofibroblast cells express α-SMA during 
type 2 EMT, this contributes to tissue fibrosis. In breast cancer, α-SMA has 
been associated with type 3 EMT and α-SMA has mostly been detected in 
tumours of the basal phenotype (Sarrió et al., 2008). β-catenin is located on 
the intracellular side of the cytoplasmic membrane in normal epithelial cells 
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and in non-invasive cancer cells. Here it plays a role in cell-to-cell adhesion 
linking cadherin molecules to the actin cytoskeleton; it also has a central role 
as a transcriptional co-activator in the Wnt signalling pathway (Hatsell et al., 
2003). Following activation of Wnt signalling, β-catenin translocates from the 
cytoplasm to the nucleus, where it regulates several genes promoting 
invasion, growth and cell transformation including c-MYC and cyclin D1 (Guo 
et al., 2006). Vimentin, a type-III intermediate filament (IF) is a highly 
conserved 57-kDa protein. Vimentin IFs are markers of EMT that are 
constitutively expressed in mesenchymal cells, in endothelial cells lining blood 
vessels, renal tubular cells, macrophages, neutrophils, fibroblasts, and 
leukocytes (Kidd et al., 2014). A frequent alteration observed in a range of 
solid tissue malignancies is a switch in the levels of different types of IFs, for 
example cytokeratin, to the mesenchymal IF marker vimentin (Palmieri et al., 
2003). Vimentin and keratins function to direct different membrane-associated 
proteins to the membrane (Toivola et al., 2010). Vimentin expression has been 
shown to be associated with the cellular formation of invadopodia during 
migratory and invasive processes. For example, when vimentin expression 
levels were reduced by interfering RNA (siRNA) a significant fall in the 
generation of invadopodia was observed in MDA-MB231 cells (Schoumacher 
et al., 2010). It is clear that a multitude of microenvironmental signalling events 
lead to the induction of EMT; these include TGF-β/smad, Notch, Wnt, TNF-
α/NF-κB and RTK signalling (Wu and Zhou, 2010). These signals activate 
several transcription factors such as the snail/slug family, twist, δEF1/ZEB1, 
SIP1/ZEB2 and E12/E47. These transcription factors then recruit cofactors 
and histone deacetylases to E-Box DNA sequences located near the 
transcription initiation site of E-cadherin. snail was the first transcription factor 
identified shown to result in repression of transcription of E-cadherin and 
subsequently a fundamental role has been ascribed to snail in terms of EMT 
processes (Barrallo-Gimeno and Nieto, 2005). In addition to E-cadherin, snail 
may down-regulate the expression of epithelial markers including claudins, 
occludins, and mucin-1, and induce expression of genes activated in 
mesenchymal and invasive phenotypes (Wu and Zhou, 2010).  
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Another important class of molecules implicated in physiological and 
pathological EMT pathways are the matrix metalloproteases (MMP). Over the 
last three decades, elevated MMP levels have been shown to occur in diverse 
tissue pathologies, as well as in cancer (Deryugina and Quigley, 2006). 
Studies of tumour tissue samples from patients have shown a positive relation 
between tumour metastasis and expression levels of MMP1, -2, -3, -7, -9 and 
-13, MMPs have also emerged as valuable prognostic factors for solid tumours 
(Deryugina and Quigley, 2006). Hotary et al demonstrated that MT1-MMP, 
MT2-MMP and MT3-MMP but surprisingly not MMP2 and MMP9 (which are 
secreted type-IV collagenases) are associated with the breast cancer cell line 
MDA-MB231 ability to breach the basement membrane. In addition, it has 
been shown that MT1-MMP is able to degrade the collagen of the interstitial 
collagen network of the ECM whereas secreted MMPs do not (Hotary et al., 
2006). MT1-MMP may utilise fibronectin, vitronectin, laminin-1, fibrin, collagen 
type-I, collagen type-II, collagen type-III, CD44 and tissue transglutaminase as 
a substrate. MT1-MMP also contributes to cellular invasion through the 
activation and reassembly of MMP2. Reduced invasiveness and migratory 
ability have been observed in genetically modified MDA-MB231 cells whose 
expression of MT1-MMP was eliminated.  Higher expression levels of MT1-
MMP has also been correlated with a poorer outcome and shorter disease-





































































































































































































































































































































1.3.6 Hypoxia and EMT 
 
Recent studies have shown that a hypoxic microenvironment triggers EMT by 
regulating expression levels of transcription factors including snail, twist, slug 
and ZEB, and inducing EMT-related signalling pathways including TGF-β1 and 
NF-κB (Matsuoka et al., 2013, Renaud et al., 2014). HIFs are heterodimeric 
transcription factors which consist of an α subunit and a β subunit. Three α 
subunits including HIF-1α, HIF2α, HIF3α and two β subunits have been iden-
tified. HIF-1α is a subunit with a 200-amino acid oxygen-dependent degrada-
tion domain (ODD) which allows HIF-1α to be ubiquitylated and degraded by 
the 26S proteasome in normoxic conditions. Under hypoxic conditions, HIF-
1α gains stability through dimerisation with the HIF-1β subunit and the com-
plex induces transcription of many genes involved in EMT. However, it has 
been known that HIF-1α stabilisation is induced by HER2 overexpression and 
its downstream signalling pathways in non-hypoxic conditions (Laughner et 
al., 2001, Li et al., 2005). It has been shown that HER2 overexpressing breast 
cancer cells stabilise HIF-1α protein through PI3K and AKT pathway in non-
hypoxic conditions (Laughner et al., 2001). 
1.3.7 Tumour cell invasion into the surrounding tissue 
 
Following the liberation of cells from adherent and tight junctions, they invade 
and migrate through the surrounding stroma (connective tissue). There are 
different modes of cellular invasion these include individual, multicellular and 
collective cellular movement. The migration type and dynamic depends upon 
characteristics of the tumour microenvironment and the molecular alterations 
within the tumour (Friedl and Wolf, 2009). According to the type of migration, 
the cancer cells may display mesenchymal or/and amoeboid-like phenotypes. 
However, these phenotypes are highly plastic, and transition between them 
have been observed and reported in previous studies.  
In the case of ‘single cell invasion’ tumour cells with weak cell-cell interactions 
migrate in a random pattern independently of each other. Individual migrating 
cells may display an amoeboid-cell-like phenotype characterised by a higher 
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migratory velocity and a round cell-body phenotype, or a mesenchymal 
phenotype characterised by an elongated cell-body and relatively slow 
movement (Clark and Vignjevic, 2015). Transition between mesenchymal and 
amoeboid phenotypes has been reported. 
‘Multicellular streaming’ is another type of cancer cell migration, this is 
characterised by two or more tumour cells with either a mesenchymal or an 
amoeboid phenotype, with loose or non-adhesive properties, migrating along 
a ‘track’ in an organised manner. In vivo cellular migration of human breast 
cancer cells was investigated by Patsialou et al using intravital multiphoton 
microscopy.  Xenograft tumours of MDA-MB231 and TN1 cells (isolated from 
a patient with triple negative breast cancer) showed both individual and 
multicellular movements in both tumour types with a higher overall motility 
observed for the MDA-MB231 cells. Quantitative analysis revealed that higher 
movement velocity and longer protrusion distances in ‘multicellular streaming’ 
migration compared to random single cell patterns of migration in both tumour 
types (Patsialou et al., 2013). 
In ‘collective migration’, a group of connected cancer cells detached from the 
tumour mass, migrate into the surrounding tissues and form chord, stripe and 
sheet-like structures. This type of invasion has been observed in the 
progression of several cancers including breast, prostate, colorectal, lung and 
skin cancers as well as squamous cell carcinoma. Two groups of cells have 
been distinguished in the collective movement of cancer cells: (1) ‘leader’ cells, 
constituting the frontal edge of the invasive mass, often associated with a 
mesenchymal phenotype and (2) ‘follower’ cells; located behind the ‘leader’ 
cells the ‘follower’ cells exhibit more intercellular contacts and retain an 
epithelial phenotype. Cells at the leading edge of the invasion body degrade 
the extracellular matrix and their intracellular actin-myosin contractile 
machinery facilitates the migratory process. TGFβ has been demonstrated to 
play a role in the switch from collective to single cell invasion modes (Giampieri 




1.3.8 Resistance to cell death  
 
Programmed cell death (apoptosis) is an intrinsic mechanism for the 
maintenance of tissue homeostasis (Kerr et al., 1972). Two pathways are 
activated during apoptosis: (1) the extrinsic pathway, functioning through 
death receptors and (2) the intrinsic, mitochondrial, pathway. Initiation of 
apoptosis through either of the two pathways leads to the activation of cysteine 
aspartic acid-specific proteases (caspases), a family of conserved cysteine 
proteases that cleave cytoplasmic and nuclear protein substrates in a tightly 
regulated proteolytic cascade (McIlwain et al., 2013). Caspases have been 
classified based on their role in apoptosis and in inflammatory processes. 
Since the former is the focus of this project, the role of caspase -3, -6, -7, -8 
and -9 in apoptotic processes will be explained further in this section. 
Procaspases are inactive monomeric forms of caspases, activated by 
dimerisation: caspase -8 and –9; or cleavage: caspase -3, -6 and -7. Caspase 
–8 and –9 are classified as ‘initiator’ caspases in recognition of their 
involvement in cleavage and activation of ‘executioner’ caspases i. e., 
caspase-3, -6 and -7. On activation, an ‘executioner’ caspase activates other 
‘executioner’ enzymes, this gives rise to a feedback loop of caspase activation 
and rapid cell death. The extrinsic apoptotic pathway is triggered by interaction 
between death receptors and their ligands, these include tumour necrosis 
factor (TNF), CD95-ligand (CD95-L; also called Fas-L), TRAIL (also called 
Apo2-L), and TNF-like ligand 1A (TL1A). The intrinsic pathway is activated by 
non-receptor-mediated stimuli including cellular stresses, including growth 
factor deprivation (or lack of apoptotic inhibition), toxins, radiation, DNA 
damage, hypoxia. Activators of this pathway may include developmental 
signals that lead the cells to enter apoptosis, and, for example hormones such 
as corticosteroids and oestrogen (Elmore, 2007, Lewis-Wambi and Jordan, 
2009). On exposure to appropriate stimuli, the inner mitochondrial membrane 
of the cell loses its transmembrane potential and releases pro-apoptotic 
proteins from the intermembrane space to the cytosol, examples of such pro-
apoptotic proteins cytochrome C, Smac/DIABLO, and the serine protease 
HtrA2/Omi (Saelens et al., 2004). Cytochrome C, apoptotic protease activating 
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factor (Apaf-1), procaspase 9 and ATP combine to form the apoptosome and 
this activates caspase 9. Both intrinsic and extrinsic pathways merge at the 
execution pathway and cleavage of caspase 3 leads to the activation of 
endonucleases and proteases eventually resulting in cell death. Apoptotic 
cells are finally engulfed by phagocytic cells, identified by characteristics 
including DNA fragmentation, hydrolysis of peptide bonds in essential 
structural and nuclear proteins, cross-linked proteins, formation of apoptotic 
bodies and expression of ligands for phagocytic cell receptors (Elmore, 2007). 
A variety of pro-apoptotic and anti-apoptotic/inhibitory factors have been 
identified that regulate apoptosis. For example, the release of cytochrome C 
from mitochondria is inhibited by Bcl-2 and Bcl-XI, members of Bcl-2 family of 
proteins whose expression is regulated by p53. Other regulatory proteins 
include the inhibitor of apoptosis proteins (IAPs) a family of eight proteins 
sharing a common domain required for interaction with caspases (Hunter et 
al., 2007). A member of the IAP family, XIAP has a strong inhibitory effect on 
apoptosis by binding to activated caspase-3 and -7 and by inhibiting caspase-
9 activation (Eckelman et al., 2006). Survivin is another IAP family member 
shown to have an inhibitory role in regulating apoptosis (Altieri, 2008). The 
extrinsic pathway triggered through death receptors leads to caspase-8 
activation. This pathway is modulated by cellular FLICE-inhibitory protein 
(cFLIP) which functions by interfering with the recruitment of caspase -8 upon 
ligand binding to death receptors, thereby preventing caspase-8 activation 
(Micheau, 2003). A decrease in the levels - or other disfunctions of these 
inhibitor molecules - may result in faulty cellular apoptotic processes. Different 
mechanisms that modulate apoptosis and in human cancers have been 
revealed (Fulda, 2009) and are important as targets for development of novel 
treatments for cancer (Hassan et al., 2014). 
 Tumour microenvironment 
 
The contribution of components of the tumour microenvironment (TME) to the 
formation, growth, invasion and drug resistance of cancer cells have been 
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identified and discussed in many cancer studies and is summarised 
schematically in Figure 3. The focus of this section will be on TME constituents 
surrounding breast tumours, their possible use as prognostic and predictive 
markers and their contribution to the therapeutic treatment of the disease     
1.4.1 Biochemical phase of the tumour microenvironment 
 
Cancer cells interact with different components of the tumour 
microenvironment including cancer-associated fibroblasts (CAFs), cancer-
associated adipocytes (CAAs), endothelial cells, ECM, tumour-infiltrating 
lymphocytes (TILs) and tumour-associated macrophages (TAMs), (Yu and Di, 
2017). The ECM is the non-cellular component of the TME and is composed 
of a complex mixture of macromolecules with different biophysical and 
biochemical properties (Friedl and Wolf, 2009). These macromolecules 
include proteins, glycoproteins, proteoglycans and polysaccharides and 
constitute both parts of ECM; the basement membrane and the interstitial 
matrix. The former is more compact and porous than the latter and separates 
the epithelia and endothelia from the stroma and is composed of type-IV 
collagen, laminins, fibronectin and cross-linker proteins such as nidogen and 
entactin. In contrast, the interstitial matrix which contributes to the tensile 
strength of tissues, comprises fibrillar collagens such as type-I, type-II and 
type-III, proteoglycans and glycoproteins such as tenascin C and fibronectin 
(Egeblad et al., 2010b). Tissue architecture and integrity are influenced by the 
physical properties of the ECM including the rigidity, porosity, insolubility and 
topography. In addition, the ECM functions as a barrier, anchorage site and 
movement route, impacting cell migration and motility. The TIL population 
principally includes CD8+ cytotoxic T cells, CD4+ helper T cells and CD4+ 
regulatory T cells (Tregs). Amongst all of these, the CD8+ T cells have a major 
influence on the anti-tumour immune response particularly on TNBC tumours 
(Stanton et al., 2016). The infiltration of TILs at the invasive margin of a tumour  
Besides infiltrating lymphocytes, tumour-associated macrophages (TAMs) 
originating from monocytes are recruited by the presence of chemokines such 
as CCL2 secreted by tumour or stromal cells to the tumour area. The observed 
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polarised distribution of macrophages within tumours has led to the generation 
of two specific phenotypes, termed M1 and M2. TAMs exhibit greater 
differentiation towards the M2 phenotype. Breast cancer cells, for example 
MDA-MB231 cells, secrete factors that have been shown to promote M2 
activation and differentiation. Unlike M1-type macrophages with pro-
inflammatory impact and anti-tumour responses, TAMs may also promote an 
anti-inflammatory phenotype by releasing cytokines, for example IL-8, IL-6 and 
IL-10 and growth factors and proteases (Solinas et al., 2009). TAMs also 
facilitate metastasis through their role in inducing angiogenesis, contributing 
to matrix remodelling, augmenting tumour cell migration and invasion, and 
promoting an immunosuppressive phenotype (Qian and Pollard, 2010). 
Cancer-associated fibroblasts (CAFs) are also a significant component of the 
tumour microenvironment, and this is particularly relevant in breast cancer with 
intra- and inter- lobular CAFs described (Buchsbaum and Oh, 2016). CAFs 
have been found to promote cancer initiation, progression, invasion, 
metastasis, angiogenesis, ECM remodelling, the deposition of basement 
membrane components, cancer-associated inflammation and the regulation of 









































































































































































































































































































The interaction between CAFs and different breast cancer subtypes has been 
studied in several co-culture experiments. Takai et al reported that CAFs may 
increase TNBC progression by activating TGF-β (Takai et al., 2016). 
Upregulation of podoplanin, a lymph vessel marker, was observed in stromal 
CAFs and was associated with higher grade and TNBC (Niemiec et al., 2014). 
Increasingly the data suggests that tumour growth and development may 
occur through proliferation of breast epithelial cells producing fibroblast growth 
factor-7 (FGF-7) a potent growth factor for mammary cells (Palmieri et al., 
2003). A study of a murine model reported that cancer cell growth enhanced 
the levels of stromal cell-derived factor 1 (SDF1), a mediator of angiogenesis 
secreted by CAFs (Orimo et al., 2005). Furthermore, several studies using 
conditioned media from CAFs as well as direct and indirect co-culture with 
CAFs, indicated that CAFs induce EMT in breast cancer cells (Dumont et al., 
2013, Soon et al., 2013). Contrary to the normal fibroblasts which grow in a 
mesh-like pattern, breast CAFs deposit ECM in a parallel pattern (Dumont et 
al., 2013). A shift from epithelial to a mesenchymal phenotype was observed 
in premalignant breast cancer cells cultured in CAF-deposited ECM. Further 
analysis of this ECM demonstrated the existence of higher amounts of 
fibronectin, biglycan (a proteoglycan) and lysyl oxidase (an enzyme involved 
in ECM remodelling). 
1.4.2 Interstitial fluid flow and pressure  
 
As described above, cells found within the tumour microenvironment have 
been shown to influence tumour growth and metastasis, however, to paint a 
complete picture, one also needs to consider alongside the biological phases 
the biomechanical features of the microenvironment that has been shown to 
be altered in cancer. The interstitium is composed of two main compartments: 
interstitial fluid and ECM. Interstitial fluid transports nutrients and waste 
products between cells and the capillaries and also contains signalling 
molecules originating in distant organs or, alternatively, locally produced 
(paracrine and autocrine). In healthy tissue, postcapillary venules reabsorb the 
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major part of this fluid, and the downstream lymphatic vasculature drains the 
remaining fraction of the fluid which is ultimately emptied out into the venous 
bloodstream. However, in solid cancers, increased cell proliferation, alteration 
in ECM stiffness and architecture, and irregularities in the vasculature arising 
from the growth of new blood vessels (angiogenesis) results in a malfunction 
of this well organised system leading to an increased flow rate in tumour 
tissue. In addition to angiogenesis, lymphangiogenesis occurs in most of solid 
tumours (Swartz and Lund, 2012). Furthermore, the lymphatic vessels 
enlarge, and drainage capacity and permeability increase during progression 
of cancer. However, these alterations cannot effectively balance the increase 
in fluid exerting from the irregular blood vessels. The impaired clearance of 
extracellular fluid, a consequence of lack of functional intra-tumoural lymphatic 
vessels can result in elevated IFP within tumours with a sharp reduction in 
pressure at the tumour periphery (Farnsworth et al., 2006). 
Elevated interstitial fluid flow (IFF) in mammary tumours was first reported by 
Butler et al. in 1975, with enhanced hydrostatic pressure and lymphatic 
drainage from the interstitial space noted as well as remarkable differences in 
afferent and efferent tumour blood haematocrit levels (Butler et al., 1975). 
Since then, various techniques have been used to measure increased IFF 
including fluorescence recovery after photo bleaching (FRAP) and magnetic 
resonance imaging (MRI) (Dafni et al., 2005a). Interstitial fluid velocity in 
normal tissues and tumours has been quantified using these techniques and 
is reported in the range 0.1 to 2 µm s-1 (Dafni et al., 2005b). In a study 
conducted in 1989, the interstitial fluid velocity was measured using FRAP and 
found to be 0.2 to 0.8 µm/s. However, in tumours, shielding of the cells by the 
ECM lowers the shear stress generated by this fluid velocity (Kamiya et al., 
1988, Pedersen et al., 2010).  
Other techniques have been used to measure IFP in normal and tumour 
tissues. These have been subdivided into ‘acute’ (few hours) and ‘chronic’ 
studies of IFP.  The approaches used include invasive techniques - for 
example surgical procedures including: wick catheter (Scholander et al., 1968, 
Hargens, 1981), wick-in-needle technique (Fadnes et al., 1977, Wiig et al., 
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1987), servo-micropipette (Wiederhielm et al., 1964) polyurethane transducer-
tipped catheter (Millar) (Ozerdem and Hargens, 2005), for acute 
measurement, and subcutaneous capsule implantation for 4 to 6 weeks 
(Guyton et al., 1963) for chronic assessment of IFP. Recently, a non-invasive 
method introduced for estimating IFP in solid tumours using MRI technology, 
converting theoretical variables into measurable variables (Liu et al., 2016). 
Researchers have been studying the elevation of interstitial pressure in human 
clinical samples and mouse models for over 30 years (Baxter and Jain, 1989, 
Boucher et al., 1990, Boucher et al., 1997). In 2011, Goel et al. gathered data 
from various published studies of IFP in normal tissues and human tumours 
and reported a significant increase in IFP level in tumours, figure 4 (Goel et 
al., 2011). In 1993, Curti et al reported interstitial pressure of ≤110 mmHg in 
subcutaneous nodules in melanoma and lymphoma patients (Curti et al., 
1993). In another study using A-07 human melanoma xenografts as the 
primary tumour, increased IFP was shown to be associated with pulmonary 
and lymph node metastasis (Rofstad et al., 2002). Measurements of the IFP 
in 118 patients with oral squamous cell carcinoma suggested the IFP value as 
a significant prognostic factor for 5-year survival (Yu et al., 2014a). Elevated 
IFP in cervical cancer was significantly associated with poorer patient survival 
following radiotherapy (Milosevic et al., 2001).  Elevated IFP has also been 
associated with lymph node metastasis in patients with cervical carcinoma 
(Hompland et al., 2012), mouse models of breast carcinoma (Pathak et al., 
2006), and xenograft models of cervical carcinoma and melanoma (Hompland 
et al., 2012). These observations suggest that IFP measurement may be a 
potential prognostic tool for clinical examinations and treatment options of 










































































































































































Recently, using Boyden chambers and other engineered models, scientists 
have studied the effect of IFP on breast cancer cell behaviour including cellular 
invasion, migration and proliferation; assessing either the expression of EMT 
markers and MMPs or the migratory dynamics of tumour cells. Hence, 
elucidating molecular mechanisms through which cancer cells and stromal 
cells can sense and react to elevated IFP will provide knowledge that may help 
to guide targeted therapy. 
Responding to reports of differences in the biomechanical properties of tumour 
and normal tissues, researchers have developed various tools designed to 
recapitulate interstitial flow and pressure in the tumour microenvironment. 
Microfluidic systems are the most commonly used devices used to generate 
controlled amounts of flow and pressure in 2D and 3D cell culture systems. 
Although these systems are being produced by different manufacturers, they 
are similar in their fundamental aspects (Huh et al., 2011). In general, a 
microfluidic system is composed of a set of micro-channels engraved or 
moulded into a material (glass, silicone or PDMS) constructed on a microfluidic 
chip which is connected to a reservoir of growth media through inlet and outlet 
tubes pierced into the chip. Media and gases may be injected and removed 
from the microfluidic chip either actively via peristatic pump and pressure 
controllers or passively through hydrostatic pressure. (Boucher et al., 1990) 
The recent availability of a bioreactor system (Quasi Vivo®, Kirkstall, U.K.) 
provided a small, inexpensive but reliable method of culturing cells under flow. 
The Quasi Vivo culture unit generates pulsatile-laminar-unidirectional flow 
which is typical for arterial blood flow. The layout of this system enables 
scientists to culture two or more different cell types in the connected chambers, 
mimicking the interactions between cells which occur in a tissue. The system 
has been mainly used for quick and cost-efficient cytotoxicity testing and 
studies on cellular metabolism. It also has a potential application in the 
biotechnology, pharmaceutical, chemical, cosmetics and research industries. 
For the novel application of this bioreactor in this study, the supplier was asked 
to redesign the system to be able to generate a higher pressure in the 
chambers. According to optimisation experiments they performed, by using 4 
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flow restrictors and applying the flow of 550 µL/min in a two chambers system, 
we can increase the pressure inside the chamber to ~19 mm Hg, while the 
pressure without using the flow restrictors is ~1 mm Hg. Since 550 µL/min is 
a high flow rate, to evaluate the effect of lower flow rate (alone), a flow rate of 
150 µL/min was also applied.  
1.4.3  Interstitial flow and progression of cancer 
 
The movement of fluid passing through intercellular spaces in the ECM has 
been shown to be a factor leading to alterations in the tumour 
microenvironment. The effect of IF on cancer cells may be categorised into 
direct; the effects on the cancer cells themselves, or indirect; the impact on 
other components of the tumour such as the stromal cells and extracellular 
matrix. The direct effects of IF on cancer cells have been studied in multiple 
2-dimensional (2D) and 3-dimensional (3D) cancer models (Shieh et al., 
2011). Exposing breast cancer cells to IF in a 3D collagen model led to 
increased migration both in 3D culture inserts and in 3D flow chambers 
(Shields et al., 2007, Haessler et al., 2012).  Applying IFP was shown to alter 
expression of genes associated with EMT and promote collective invasion in 
breast cancer cells (Piotrowski-Daspit et al., 2016). These findings suggest 
fluid flow within the tumour might be a prognostic indicator of invasion and 
metastasis.    
During progression of cancer, fibroblasts are recruited and transformed to 
become cancer-associated fibroblasts (CAFs). Alterations in fluid flow and 
pressure have been reported to affect this transformation. Myofibroblasts are 
also transformed from fibroblasts and their phenotype resemble CAFs. 
Myofibroblasts are identified by elevated alpha smooth muscle actin (α-SMA) 
expression, increased contractility, and elevated secretion of MMPs, cytokines 
and growth factors involved in tumour migration and angiogenesis. TGF-β1 
secreted by cancer cells and fibroblasts, is an inducer of fibroblast to 
myofibroblast or CAF differentiation (De Wever et al., 2004, Orimo et al., 
2005). Exposure of fibroblasts to increased IFF has been shown to result in 
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the induction of TGF-β1 and consequently myofibroblast differentiation even 
in the absence of a tumour (Ng et al., 2005). Implementing IF (0.5 µm/s) in a 
coculture of dermal fibroblasts and MDA-MB-435S melanoma cells using a 
collagen matrix and modified 3D Boyden chambers, resulted in increased 
tumour cell invasion and fibroblast activation mediated by TGF-β1 (Shieh et 
al., 2011).  
 In vivo models of breast cancer  
 
It would be of great value to be able to test drug efficacy and the resistance of 
cancers to certain drugs by assessing the drug responsiveness of primary 
tumour cells (from patients), this could be evaluated either in vivo or in vitro 
ultimately at the outset, when clinical treatment commences. Several in vitro 
and in vivo strategies are being developed in an attempt to tackle this issue. 
Amongst all kinds of in vivo strategies, ‘Mouse Avatar’ and ‘Co-clinical Trials’ 
are the most advanced projects so far. The main focus of the co-clinical trial 
project is to use either genetically engineered mouse models (GEMMs) or 
patient-derived tumour xenografts (PDTX) to guide patient therapy in on-going 
human clinical trials. In this paradigm, mouse trials and human trials are 
developed in parallel to provide fast and real-time transfer of outcomes from 
mouse treatment to human clinical trials, Figure 5 (Nardella et al., 2011). On 
the other hand, ‘Mouse Avatars’ use patient-derived tumour xenografts 
(PDTX) with the aim of helping clinicians choose optimal chemotherapeutic 
agents (Marangoni and Poupon, 2014). Although the concept of tailoring 
therapy with this approach is appealing, studies have indicated technical 
drawbacks both in terms of scientific and non-scientific limitations (Mueller and 
Reisfeld, 1991). For example, the maintenance of these in vivo models is very 
expensive, leading to claims that the systems are ultimately unaffordable, 
moreover, because the xenograft models encompass several steps including 
implantation, propagation and drug-screening, the time required before 
determining the optimum treatment protocol remains a problem and patient 


























































 In vitro tissue culture models of breast cancer 
 
In addition to in vivo models, several in vitro systems have been developed 
with the aim of stratifying breast cancer patients to different treatment 
regimens. Although conventional monolayer (2D) cell culture models are 
convenient to set up and have been used in different areas of biological 
research for decades, they have limitations in terms of the physiological 
relevance of these methods for detailed tumour studies. Despite the increased 
complexity that may be developed in a 2D cell culture environment, for 
example using stromal cell co-culture, the limitation of 2D cell culture for 
capturing tumour heterogeneity is well accepted (Debnath and Brugge, 2005). 
The microenvironment that surrounds cancer cells within a solid tumour 
consists of cellular components including stromal cells, infiltrating immune 
cells, lymphatics, vasculature and acellular components including the ECM, 
growth factors and cytokines. Several methods have been developed that aim 
to provide a complex cell culture system that includes the interplay between 
these components and cancer cells, a phenomenon that occurs in the in vivo 
condition.  
Recently, a range of 3D models have been developed to better reflect the 
complexity of tumours. As a general concept, 3D cancer models can be 
divided into two main categories: ECM inclusive and ECM exclusive 
(spheroids). Tumour cells have been maintained in cell culture as spheroids 
since the 1970s and have been used in a range of studies including those 
aimed at the formation of the breast acinar structure and breast tumour models 
(Debnath and Brugge, 2005). The techniques and devices that have been 







Technique Device Reference(s) 
Hanging drop 
method 












et al., 2018, 
Kwok et al., 
2018) 
Magnetic levitation magnetic nanoparticles (Souza et al., 
2010) 
Table 1. The key methods developed for the preparation of cancer cell spheroids.  
 
A feature of each of these techniques is that the cancer cells are prevented 
from adhering to the surface of the wells/vessels and forced to aggregate and 
form spheroids (Hoarau-Véchot et al., 2018). Adding stromal cells such as 
fibroblasts and endothelial cells and applying magnetic levitation has improved 
the physiology and reproducibility of the spheroid-based experiments 
(Gottfried et al., 2006, Kunz-Schughart et al., 2006). Several morphological 
characteristics for example epithelial-myoepithelial interactions and drug 
response have been studied using spheroids. The preparation of cancer cell 
spheroids has allowed investigations aimed at understanding the resistance 
of cancer cells to cytotoxic agents such as doxorubicin and cisplatin (Kerr et 
al., 1986, Kobayashi et al., 1993, Frankel et al., 1997). 
A drawback of this approach, however, is that the ECM, a key component of 
the tumour microenvironment, is generally omitted when spheroids are 
prepared suspended in culture medium. To address this shortcoming, 
scientists have created 3D scaffolds with the aim of recapitulating the ECM as 
an essential natural environment.  This approach recognises the role of the 
ECM in both intra- and extra-cellular signalling, cell proliferation, 
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differentiation, migration, invasion and drug uptake. Biodegradable and 
biocompatible scaffold materials used in cancer biology applications are 
usually classified into two main groups: (1) naturally derived matrix materials 
including collagen, fibronectin, laminin and hyaluronic acid; and (2) synthetic 
polymer-based materials such as poly (lactic-co-glycolic) acid (PLGA) and 
poly-ε-caprolactone (PCL)(Rijal and Li, 2016) Engelbreth-Holm-Swarm ECM 
extract (Matrigel) material, collagen and decellularised ECM are the most 
commonly used biomaterials for modelling breast tumours as they offer 
support for cell growth, differentiation and migration compared to synthetic 
materials. The trend toward the use of different synthetic and natural 
extracellular matrix has been reviewed by Rijal et al (Rijal and Li, 2016). 
  Naturally derived matrix materials 
 
The main constituents of the ECM in mammalian tissues are collagen, elastin, 
laminin and proteoglycans (Frantz et al., 2010). The design of a 3D tissue 
culture to mimic the natural structure of the ECM in human tissues as closely 
as possible would, therefore, include collagen, MatrigelTM and fibronectin. To 
this end gelatin, alginate, chitosan and silk fibroin have been tested but these 
are from non-human sources. Collagen type-I has been the most commonly 
used scaffolding material used for modelling of breast tumours either alone or 
in combination with other components of the ECM tissue such as fibronectin, 
laminin, hyaluronic acid and MatrigelTM (Rijal and Li, 2016). Collagen is the 
most abundant protein of human connective tissue and is categorised to 28 
types of either fibrillar or non-fibrillar forms. 
Fibrillar type-I collagen accounts for 90% of collagen found in the human body 
and has been the most frequently used natural material for 3D culture and 
tissue engineering studies.  In humans, collagen type-I fibrils are mainly 
present in skin, tendon, vascular ligature, organs and bone whilst in the normal 
mammary gland, interstitial ECM contains fibrillar collagens (I, III and V) and 
basement membrane contains the non-fibrillar type-IV collagen. In breast 
cancer a reduction in the levels of collagen IV and an increase in levels of 
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collagen I, III and V has been reported (Egeblad et al., 2010a, Oskarsson, 
2013). Earlier studies of malignant tumours showed that the expression levels 
of mRNA for type-I and type-III procollagen increased in the fibroblastic cells 
resident in the stroma. Furthermore, an in vivo study of a ductal infiltrating 
breast carcinoma reported increased deposition of bundles of collagen type-I 
and III at the invasive front of the tumour (Kauppila et al., 1998).  
Cancer invasion requires remodelling of the ECM - this is primarily facilitated 
by the degradation of collagen, re-deposition, cross-linking and stiffening and 
is accompanied by infiltration of immune system cells and re-differentiation of 
monocytes at the invasive front. During tumorigenesis, the smooth and twisted 
structure of collagen characteristic of normal breast tissue alters to become a 
stiff, thick and linear collagen, this is associated with a change in epithelial cell 
polarity and alterations in cell–cell adhesion, this in turn enhances growth 
factor signalling, EMT and invasion, features associated with a metastatic 
phenotype (Egeblad et al., 2010a). Increases in ECM cross-linking alongside 
deposition of fibronectin, proteoglycans and collagens I, III and IV have been 
reported in other types of invasive cancers (Zhu et al., 1995, Huijbers et al., 
2010). The mentioned modifications may lead to generation of invasion 
‘highways’ for cancer cells whereby cells migrate along the collagen fibres.  
Drug delivery and drug efficacy has been shown to be affected by collagen 
density and other physical and molecular features of the ECM network 
(Egeblad et al., 2010a).  
In addition to material derived from mammalian tissues, other biomaterials 
extracted from natural sources, have been used as biodegradable scaffolds. 
For example, MCF-7 breast cancer cells grown on the polymeric 
polysaccharide chitosan (produced from the chitin of the exoskeleton of 
crustaceans), showed growth kinetics comparable with those cultured in tissue 
culture flasks (Dhiman et al., 2004). MDA-MB231 cells cultured on silk fibrin 
scaffolds displayed enhanced MMP-9 activity, suggesting a higher invasion 
potential of the cells when grown in 3D culture. Concurrently it was reported 
that the cells produced the same yield of lactate from glucose consumption as 
in vivo conditions, indicating that the scaffolds were able to maintain the 
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metabolic activity of the MD-MB231 cells (Jastrzebska et al., 2015). In various 
studies mixtures of different natural biomaterials have created unique scaffold 
structure with improved biophysical and biochemical properties. For instance, 
a mixture of silk fibroin and chitosan results in a unique scaffold with more 
fibro-porous structure which is non-toxic and highly permeable for water and 
oxygen, supporting cell growth and adhesion (Li et al., 2017). The multitude of 
studies with different matrices and cell types have shown the importance of 
cell culture methods on cell growth, invasion and drug responsiveness. 
Elucidating the molecular mechanisms that might be affected in response to 
different microenvironments, will provide the more reliable cell culture methods 
for use in the drug discovery process. It may also aid the development of novel 
methods for personalised therapy strategies.  
 Doxorubicin and resistance to therapy 
 
Doxorubicin, a chemotherapeutic drug with a molecular weight of 543 g/moL, 
was first extracted from Streptomyces peucetius var. caesius in the 1970’s 
(Arcamone et al., 1969). Doxorubicin belongs to the anthracycline category of 
chemotherapeutics which act through the intercalation of DNA, inhibition of 
topoisomerase II and the formation of free radicals (Tacar et al., 2013). Since 
it was discovered doxorubicin has been in routine use for the treatment of a 
range of cancers including breast, lung, gastric, ovarian, thyroid, non-
Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and 
paediatric cancers (Lao et al., 2013, Rathos et al., 2013, PDQPTE, 2002, Saini 
et al., 2018). In clinical practice, doxorubicin is administered 
independently/alone or in combination with other chemotherapeutic or 
targeted biological agents or encapsulated in liposomes or other nanoparticle 
materials for treatment of various types of cancers. Since breast cancer cells 
were used in this project, the primary focus was the toxicity of doxorubicin on 
breast cancer cells.  
Current approaches for the adjuvant therapy of breast cancer is a combination 
of anthracyclines, such as doxorubicin and epirubicin; taxanes, including 
paclitaxel and docetaxel, along with fluorouracil and cyclophosphamide 
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(Hernandez-Aya and Gonzalez-Angulo, 2013). However, resistance to 
chemotherapy has been reported for many breast cancer patients. Such 
resistance mechanisms may be acquired after exposure to the therapeutic 
agent or may be inherent characteristics which exist in the tumour prior to 
treatment, figure 6.   
Cancer cells may acquire resistance to therapy as a result of the accumulation 
of mutations and sequential genetic changes occurring during the 
development of cancer over time. Acquired resistance may occurs in cancer 
cells which have survived exposure to an initial therapeutic regimen, whilst 
inherent (de novo) resistance is associated with intrinsic factors within the 
cancer cells themselves. Resistance may also be mediated by environmental 
factors such as the attachment of the cancer cells to the ECM (Dittmer and 
Leyh, 2015). As an example, culturing MCF-7 and MDA-MB231 breast cancer 
cells in 3D ECM-based model has been shown to result in a reduction in 
doxorubicin efficacy. However, the application of a β1-integrin blocking 
antibody prior to addition of doxorubicin to MDA-MB231 cells cultured in ECM 
(Matrigel), resulted in a significant increase in sensitivity of MDA-MB231 cells 
to doxorubicin in a dose dependent manner (Lovitt et al., 2018). This approach 
has indicated the importance of understanding molecular mechanisms 
underlying interaction of tumour cells with the microenvironment and a 
potential route through which cancer cells may acquire resistance to therapy. 
This should be noted with regards to chemotherapeutic drugs when a non-
responsive patient receives serious life-threatening side effects without 






































































































































































































































































































































































































































































 Aims and objectives 
 
The aim of this project was to study the effect of the tumour microenvironment, 
in particular, fluid flow and pressure, on breast cancer cell behaviour and re-
sponsiveness to the chemotherapeutic agent doxorubicin. 
The long-term aspiration for this research was to create an in vitro tumour 
model which would provide a more physiologically relevant environment for 
studying molecular mechanisms underlying breast tumour growth and inva-
sion and for evaluating drug efficacy in drug discovery processes. 
The objective in the first part of the project was to compare the behaviour and 
sensitivity of breast cancer cells to doxorubicin when cells were grown (1) in 
2D culture; (2) in 3D spheroids and (3) in 3D after embedding in collagen type-
I using the RAFT system to form 'artificial cancer masses' (ACM).  The second 
focus of the project was an assessment of the biochemical effect of interstitial 
fluid flow and pressure on tumour cell invasion, levels of markers of EMT, pro-
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 Materials and equipment 
2.1.1 General reagents, buffers and other chemicals  
The details of general chemicals and reagents used in this study are listed in 
Appendix 1. 
2.1.2 Media, buffers, reagents and consumables used in cell 
culture, cell harvest and cell lysate processes  
 
High glucose (4.5 g/L) Dulbecco’s modified Eagle’s medium (DMEM) 
(Hyclone, Life Technologies, U.K.); foetal bovine serum (FBS) (Gibco, Life 
Technologies, U.K.); Trypsin-EDTA Solution 10X (Sigma-Aldrich, U.K.); Rat 
Tail Collagen Type-I >2 mg/mL Chloroform Treated (First Link Ltd, U.K.); 
Phosphate-Buffered Saline (PBS) (Gibco, U.K.); Minimum Essential Medium 
(MEM) (Lonza, U.K.); Antibiotic Antimycotic Solution 100X (Sigma-Aldrich, 
U.K.); Neutralising buffer (1.6 M NaOH in 840 mM HEPES buffer) (home- 
made); RAFT™ absorbers for 96-well and 24-well plates (Lonza, U.K.); 
Collagenase type-I (Gibco, U.K.); Hanks’ Balanced Salt solution (HBSS) 
(Sigma, U.K.); RIPA Buffer (Sigma, U.K.); 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (Thermofisher Scientific, USA). 
2.1.3 Kits 
2.1.3.1  RNA extraction, cDNA library construction and 
quantitative polymerase reaction (qPCR) 
 
The RNeasy Micro Kit was used to extract RNA from the cancer cells the 
QuantiTect Reverse Transcription Kit was used to produce cDNA from mRNA 
(Qiagen Ltd, U.K.). Gene expression levels were measured using the 




2.1.3.2  Protein measurement kit 
 
The Pierce™ BCA Protein Assay Kit was utilised to measure total protein 
concentration in the cell lysates (Thermofisher Scientific, USA).  
 
2.1.3.3  Alamar blue reagent  
 
The metabolic activity of cells cultured in 2D and 3D was measured using the 
Alamar blue reagent kit (Invitrogen, U.K.) 
 
2.1.4 Electrophoresis buffers and reagents 
2.1.4.1  Agarose gel electrophoresis 
 
The integrity of extracted RNA and the size of qPCR products were assessed 
using agarose gel electrophoresis. The materials used were: agarose (Sigma, 
U.K.), Gel Red (Biotium, USA), tris-borate-EDTA buffer 1X (homemade TBE: 
108 g Tris, 55 g boric acid, 40 mL 0.5 M Na2EDTA, pH 8.0 in 900 mL distilled 
water), loading buffer (home-made). DNA Gel Loading Dye (6X) (Thermofisher 
Scientific, USA), DNA ladder (New England Biolabs, USA).  
 
2.1.4.2  Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Separation of proteins was carried out using SDS-PAGE. The following 
materials were used: acrylamide/bis-acrylamide 30% v/v (Sigma, U.K.); 
sodium dodecyl sulphate (SDS) (Sigma, U.K.); running buffer: 14.4 g Tris 
base, 3.03 g glycine and 1 g SDS, loading buffer 2x (Sigma-Aldrich, U.K.), Tris 
–HCl pH, 6.8, Tris HCl pH, 8.8, catalysts: N,N,N′,N′-
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Tetramethylethylenediamine (TEMED) (Severn Biotech Ltd, U.K.) and 
ammonium persulfate (APS) (Sigma-Aldrich, U.K.); Precision Plus Protein 
Dual Colour Standards (Bio-Rad, U.K.). 
2.1.5  Western blotting reagents  
 
Transfer buffer (25 mM Tris, 0.2 mM Glycine, 20% v/v methanol, pH 8.3); 
Ponceau S solution (Sigma, U.K.); filter paper (Thermofisher Scientific, USA); 
Nitrocellulose Membrane (Thermofisher Scientific, USA); enhanced 
chemiluminescent (ECL) substrate (Thermofisher Scientific, USA), bovine 
serum albumin (BSA) (Sigma, U.K.). phosphate-buffered saline with 0.05% 
Tween-20 (PBST). 
 
2.1.6  Antibodies  
 
Antibodies used for immunostaining of the cells and Western blot analysis. 
 
2.1.6.1  Primary antibodies 
 
Rabbit monoclonal anti-ErbB 2 antibody (ab134182, Abcam, U.K.); rabbit 
monoclonal anti-vimentin (Cell Signalling Technology, USA); rabbit polyclonal 
anti-β-actin antibody (Abcam, U.K.); rabbit polyclonal anti GAPDH antibody 
(Abcam, U.K.). 
 
2.1.6.2  Secondary antibodies 
 
Goat polyclonal anti-rabbit IgG H&L (HRP) pre-adsorbed (Abcam, U.K.); goat 





Doxorubicin was used in its hydrophilic form (doxorubicin hydrochloride) from 
Thermofisher Scientific.  
 Methods 
2.2.1 Cell culture  
 
Human breast cancer cell lines, MDA-MB231 and SKBR3 (available at the 
University of Westminster, purchased from ATCC).  Normal fibroblast cells 
isolated from breast tissue outside the cancer margin and distal to the cancer 
growth were kindly provided by Dr Hazel Welch, Division of Surgical and 
Interventional Sciences, Royal Free and University College London Medical 
School, University College London. The cells were cultured in monolayer (2D) 
and multilayer/matrix (3D) formats.  
 
2.2.1.1  2D monolayer cell culture 
 
MDA-MB231, SKBR3 and normal fibroblast cells were cultured in high glucose 
Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone, Life Technologies) 
supplemented with 10% v/v foetal bovine serum (FBS) (Gibco, Life 
Technologies) and maintained in a humidified atmosphere at 37oC in 5% v/v 
CO2.  For routine passage, the cells were allowed to reach 80% confluency, 
the media was removed, cells were washed by PBS twice, 10X trypsin-EDTA 
was added to detach the cells from the surface of the cell culture flask and 
from each other. Due to the different cell attachment properties across the cell 
lines, the incubation time in this step ranged from 30 to 60 seconds for MDA-
MB231 cells and 3 minutes for SKBR3 cells. Cells grown as 2D monolayers 
were transferred to a collagen scaffold for the preparation of the 'artificial 
cancer mass' (ACM) system as described below.  
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2.2.1.2   Three-dimensional tumour models 
 
An artificial cancer mass (ACM) was prepared using the RAFT 3D cell culture 
system in 96-well plates, following the manufacturer’s instructions (Lonza, 
U.K.). An overview of the preparation of the ACM is shown in Figure 7. The 
proportions of reagents used for constructing ACMs are shown in table 2. In 
brief, 2.8 mL of minimal essential medium (10X MEM) was added to a mixing 
vessel, then, slowly 22.4 mL of rat-tail collagen type- I (2 mg/mL) was added, 
care was taken to avoid introducing air bubbles, swirling the solution carefully 
around the mixing vessel. The solution was neutralised by addition of 1.624 
mL of neutralising solution (1.6 M NaOH in 840 mM HEPES buffer). A solution 
containing the cells (cell stock solution) prepared previously and added to the 
collagen type- I scaffold mixture slowly.  
The number of cells in the cell stock solution for seeding 50,000 cells per well 
required 1.92 x106 cells per plate in the cell stock solution. The final mixture of 
collagen-MEM-cell solution was mixed gently and aliquoted into the 96-well 
plate (240 µL per well) and placed in the incubator set at 37 oC for 15 minutes  
to form a cell populated collagen hydrogel. In the next step biocompatible 
hydrophilic RAFT absorbers were placed on top of each well for 15 minutes 
(at room temperature). Absorption of liquid resulted in a 40-fold increase in the 






















96 2.8 22.4 1.624 1.200 0.240 
24-well 
plate 
24 3.5 28.2 2.042 1.500 1.300 
Table 2. Proportion of reagents used for preparation and construction of 
ACMs.   
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collagen (manufacturer’s instructions). After removal of the absorbers, in order 
to prevent the gel dehydrating, 100 µL of culture medium (DMEM with 10% v/v 
FBS) was added to each 100 µM thick RAFT gel.  For preparation of the ACM 
the RAFT gel was initially embedded in a looser collagen matrix of 1.6 mg/mL 
in 24-well plate RAFT system. The gel was placed in the incubator set at 37 
oC for 15 minutes to allow it to set and then absorbers were applied for 15 
minutes to remove the liquid from the collagen (at room temperature).  After 
removing the absorbers, 1 mL of culture medium, DMEM with 10% v/v FBS, 
was added to each ACM. 
Prior to the co-culture of cancer cells with normal fibroblasts cells, the 
fibroblasts were cultured only in the 24-well plate RAFT system and not in the 
96-well plate to enable the diffusion into the media of growth factors and other 
stimuli released from fibroblasts. The fibroblast cells were embedded in the 















       


































































































































































































































































































































































































































































































































































 2.2.1.3  Applying interstitial fluid flow and pressure using the 
Quasi Vivo system  
 
A dynamic growth environment incorporating flow and pressure was created 
by using the Quasi Vivo QV500 system (Kirkstall, U.K.). This system consists 
of cell culture chambers made from polydimethylsiloxane (PDMS); a 
biocompatible, transparent and flexible silicone, reservoir bottle, inlet and 
outlet tubing and filter. All the compartments of the Quasi Vivo system are 
autoclavable and can be reused except the filter which has to be replaced for 
each experiment.  
To construct the circuit in the Quasi Vivo system a ‘series’ configuration was 
used. The two chambers containing the cells were plugged in sequence by 
connecting the outlet tubing of the first chamber, in the direction of flow, to the 
inlet tubing of the second chamber. In turn, the outlet tubing of the second 
chamber was connected to the 'return tubing' enabling the media to return to 
the reservoir bottle through a length of outlet tubing (2.4 mm) and a Luer lock.  
A length of smaller diameter tubing (1.6 mm) was used to connect the inlet of 
the first chamber to the reservoir bottle using a Luer lock. The tubing was 
mounted on a peristaltic pump roller enabling the transfer of the media from 
the reservoir bottle to the chambers in a circulatory flow system (Figure 8A). 
Dimensions and materials of different compartments of the Quasi Vivo QV500 
system are shown in Table 3.  
Cells cultured in 3D as ACMs were allowed to settle for 48 hours before being 
transferred to the Quasi Vivo QV500 chamber. The flow of media was 
generated using a Masterflex peristaltic pump housed in the 37oC, 5% v/v CO2, 
humidified incubator (Figure 8C). The pump produced a pulsatile-laminar-
unidirectional flow of the media in the Quasi Vivo circuit at various flow rates. 
However, other variables including number of chambers, the diameter and 
length of the tubing, the position of chambers and reservoir in relation to the 
pump and the type of pump, may affect the actual flow rates in the system. 
Hence, the system was calibrated for every new design and flow rate to ensure 




Chamber width  15 mm internal 
Chamber depth 
10 mm from culture surface to top of chamber 
base 
Materials 
Chamber: PDMS; Tubing: Tygon; Luers & 
reservoir bottle: polypropylene 
Overall dimensions 23 mm height x 37 mm diameter 
Diameter of tubing Inlet: 1.6 mm; Outlet: 2.4 mm 
Volume of chamber 2 mL 
Table 3. Specification of Quasi Vivo® system 
The suppliers of the Quasi Vivo system (Kirkstall U.K.) estimated that a flow 
rate of 550 µL/min corresponds to an interstitial fluid pressure, IFP, of 1.1 mm 
Hg (personal communication to T. Azimi. This IFP is consistent with the 
pressure in normal breast tissue. Four one-way Luer check-valves, female-
male styrene acrylonitrile (SAN) with silicone diaphragm (Cole-Parmer, U.K.) 
were used to restrict the flow and consequently increase the pressure inside 
the chambers to 19 mmHg (Figure 8B). These valves that are referred to 'flow 















































































































































































































































































































2.2.1.4  Calibration of the Quasi Vivo system 
 
The Masterflex peristaltic pump used in this study was used initially. First, in a 
series configuration, the two chambers were filled with sterile PBS buffer and 
the pump was allowed to flow. After the air bubbles were expelled from the 
system the liquid output was collected from the final chamber over a minute 
and weighed. This procedure was repeated three times and the mean average 
value indicated the flow rate (µl min-1) of the liquid in the system. Using this 
method, the flow rate was measured and adjusted according to the experiment 
undertaken, varying the pump speed, with and without flow restrictor(s).  
2.2.2 Immunostaining  
 
Cells seeded in 2D and 3D (ACMs) were immunostained to determine cell 
invasion pattern and expression of specific proteins including HER2 and 
vimentin at cellular level. The protocol used for immune staining cells in 2D 
had been optimised previously in Dr. Dwek’s lab. ACMs were stained using 
the optimised protocol kindly provided by Judith Pape from UCL.  
 
2.2.2.1  Immunostaining of cells in 2D (monolayer) 
 
Cells were grown in 6-well plates (2D) for a week in order to keep the growth 
conditions as close as possible to cells grown in 3D. After the cells reached 
70-80% confluency, they were washed with PBS and fixed for 30 minutes in 
10% V/V formalin in PBS (pH 7.4). Formalin was washed away, and PBS was 
added to each well. The cells were left in the fridge (4 oC) until they were used 
for immunostaining. Before starting immunostaining, process PBS was 
removed and 5% BSA in PBS (blocking solution) was added. The plate gently 
was incubated rocking at room temperature for 30 minutes. The wells were 




antibody was diluted in PBS by following the manufacturer instruction. Primary 
antibodies and their optimum concentration used are listed in table 4. The 
diluted primary antibody was added to the wells and incubated gently rocking 
at room temperature for 1 hour or in cold room overnight.  Then wells were 
washed three times for 5 minutes in PBS buffer gently rocking. 
Cells were incubated with secondary fluorescent labelled antibody: goat anti-
rabbit IgG (Alexa Fluor 488) at the final concentration of 10 µg/mL in PBS at 
room temperature and for an hour while gently rocking. From this step onward, 
the ACM was housed under aluminium foil to prevent the Alexa Fluor quench-
ing. Cells were washed with PBS three times for 5 minutes. In order to coun-
terstain the nuclei, To-Pro-3 dye or DAPI was used. Before using To-Pro-3, in 
order to remove RNA in the cytosol, cells were incubated with ribonuclease A 
(Sigma, U.K.) at the concentration of 100 µg/mL at room temperature for 20 
minutes. Then wells were washed with PBS twice for 5 minutes and incubated 
with To-Pro-3 (Life Technology, USA) at 1 µM in PBS at room temperature, 
gently rocking for 20 minutes. Then wells were washed three times for 5 
minutes in PBS. For the negative control, the addition of primary antibody was 
omitted and all other steps in the protocol was applied. 
 
Antibody Concentration Supplier 
Goat anti-rabbit IgG 
(Alexa Fluor 488) 
10 µg/mL Abcam 
Anti-ErbB2  1.228 µg/mL Abcam 
Anti-vimentin Dilution: 1/100 Cell Signalling 
Technology 






2.2.2.2   Immunostaining of cells in 3D (ACM) 
 
Cells grown in 3D in 24-well plates were washed three times with PBS and 
fixed in 4% w/v formaldehyde for 30 minutes. ACMs were permeabilised with 
1% w/v BSA, 0.2% v/v Triton in PBS at room temperature for 1 hour and 
washed with PBS three times for 5 minutes. The primary antibody was diluted 
to the same concentration used in 2D staining in 1% w/v BSA, 0.2% v/v Triton 
in PBS and was applied to the ACM and incubated at 4 oC overnight. The 
following day the ACMs were equilibrated to room temperature for 1 hour and 
washed three times with PBS, each wash for 5 minutes. The secondary 
antibody: goat anti-rabbit IgG, Alexa Fluor 488 was prepared in 1% w/v BSA, 
0.2% v/v Triton in PBS at the same concentration used for the 2D 
immunostaining and allowed to incubate for 2.5 hour at room temperature. The 
rest of the experiment was undertaken under aluminium foil to avoid Alexa 
Fluor quenching. The ACMs were washed three times with PBS for 5 minutes 
each and the nuclei of the cells stained with DAPI. 
 
2.2.3 Harvesting cancer cells for gene and protein analysis 
 
MDA-MB231 and SKBR3 cells cultured in 2D monolayers were washed with 
PBS and detached from the culture surface using trypsin-EDTA 10X (Sigma, 
U.K.) for 30 - 60 seconds. Since the spheroids were not attached to the surface 
and were floating in the well, trypsin-EDTA treatment was not needed and 
spheroids of 5 wells were pooled together in a Falcon tube. 10 mL media (high 
glucose DMEM) was added to the cells and was centrifuged in a Falcon tube 
at 1500 RPM for 5 minutes. To remove all the phenol-red dye from the DMEM 
the cell pellet was re-suspended in 3 mL PBS and re-centrifuged at 1500 RPM 
for 5 minutes, the PBS was removed, and the cell pellet was either stored at -




To harvest cells cultured in ACMs, firstly, the ACMs were treated with 200 
units/mL collagenase I (Gibco, U.K.) in HBSS buffer (450 µL) for each ACM) 
for 60 minutes in a plate shaker incubator (Stuart, U.K.). When the collagen 
had solubilised, the mixture was centrifuged at 1700 rcf for 5 minutes and the 
cell pellet used for the RNA extraction or for the Western blot analysis pur-
poses. 
2.2.4 Cell lysate preparation for SDS-PAGE 
 
The cells harvested from 2D cell cultures and ACMs (as described in section 
2.2.3) were lysed using the mixture of RIPA buffer (Sigma, U.K.) and 10% v/v 
protease inhibitor cocktail (Sigma, U.K.). The number of cells cultured in 3D 
was 50,000 cells per ACM and for each experiment only two ACMs were used 
(since only two quasi vivo chambers were used in each run). Therefore, in 
order to increase the protein concentration only 100 µL of RIPA buffer and 
proteinase A mixture was added to the two pooled ACM. The cells cultured in 
2D (~106 cells) were lysed using 500 µL RIPA buffer mixture. Cells were mixed 
with RIPA buffer and protease Inhibitor by pipetting and maintained on iced 
water for 15 minutes. The resulting cell lysate was centrifuged at 13,000 RPM 
at 4 oC for 15 minutes. The supernatant was carefully collected in a new sterile 
tube and stored at -80 oC until use. 
2.2.5 Bicinchoninic acid (BCA) Protein assay 
 
The protein concentration of cell lysates obtained from the cells cultured under 
different growth conditions was estimated using the BCA kit (Thermofisher 
Scientific, USA). The assay was performed by following the instructions 
provided by manufacturer. In brief, a working solution was prepared by mixing 
50 parts of reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) and 1 part 




= 125- 2000 µg/mL) was prepared by serial dilution of bovine serum albumin 
(BSA) standard solution at a stock solution concentration of 2 mg/mL provided 
by the manufacturer. For microplate-based procedures, 200 µL working 
solution and 10 µL of sample (standard/cell lysate/RIPA buffer) were added to 
each well and mixed thoroughly on a plate shaker for 30 seconds. Since RIPA 
buffer had been used for lysing the cells, it was added into the blank well. The 
plate was covered and incubated at 37 oC for 30 minutes after which the plate 
was allowed to cool to room temperature and the absorbance read at 562 nm 
(Spectrostar, BMG LabTech, Germany). A standard curve was prepared, and 
the equation of the line used to calculate protein concentration, using the 
absorbance values of the lysate samples (Appendix 2). 
2.2.6 SDS polyacrylamide gel electrophoresis (PAGE) 
 
SDS-PAGE was firstly introduced by Ulrich K. Laemmli in 1970. The technique 
was used to separate proteins in the cell lysates. A Mini-protein 
electrophoresis system (Bio-Rad Laboratories, U.K.) was used for these 
experiments. The reagents used for two gels with gel dimensions 7.0 x 8.3 cm 
(H x W); 1 mm thickness are shown in Table 5. 
The ingredients of resolving and stacking gels were mixed according to the 
proportions shown in Table 5.  A set of clean glass plates and spacers (1 mm 
thickness) was assembled in a gel holder on a casting stand. After checking 
the system for leaking and being assured that system is properly sealed, the 
10% w/v ammonium persulphate and TEMED were quickly added to the 
resolving gel mixture. 2.5 mL of the gel mixture was poured in the space 
between the glass plates, overlaid with water and left to polymerise for 15 
minutes.  The water was poured off and 4% stacking gel was prepared with 
the same procedure and poured on top of the polymerised resolving gel. A 1 
mm comb was inserted between the glass plates in order to form the wells for 
loading the samples. After the gel was polymerised, the comb was removed, 




module, placed in the tank, and top and bottom of gel was covered with 
running buffer (Tris base 14.4 g, glycine 3.03 g and SDS 1 g). 
The cell lysate samples were mixed with Laemmli sample buffer (2X) (Bio-
Rad) in 1:1 ratio, heated for 5 minutes at 100 oC, centrifuged briefly and loaded 
on the gel. 10 µL of protein standard (Bio-Rad, U.K.) was also loaded on the 
gel to estimate the size of bands after detection step. The gel was electro-
phoresed for 120 minutes at 110 V. Two gels were run for each analysis, one 
to evaluate SDS-PAGE protein separation and the other used for Western 
blotting. 
 




4 mL 0.5 mL 
1.M Tris-HCl (pH 8.8) 2.5 mL - 
MilliQ water 3.3 mL 2.1 mL 
10% SDS 100 µL 30 µL 
0.5M Tris HCl (pH 6.8) - 0.380 
Before pouring the gel 
10% Ammonium per-
sulphate 
100 µL 30 µL 
TEMED 4 µL 3 µL 
Table 5. Quantity of reagents used for SDS-PAGE 
2.2.7 Coomassie Brilliant Blue staining of protein gels 
 
After SDS-PAGE, protein bands were visualised by staining the gel with 




stained in a mixture of H2O, methanol, and acetic acid in a ratio of 50/40/10 
(v/v/v).  
2.2.8 Western Blotting (wet blot) 
 
Western blotting was performed using the method initially developed by 
Towbin et al. (1979). However, some modifications were made in the 
procedures. A Mini Trans-Blot Cell (Bio-Rad, U.K.) was used for this 
experiment. For each gel, one piece of nitrocellulose membrane (Thermo 
Scientific, USA), two pre-cut Western blotting filter papers (Thermo Scientific), 
and two fibre pads were soaked in the transfer buffer and assembled into a 
cassette in a correct orientation and order (providing the movement of proteins 
from gel to the nitrocellulose blot). The cassette was inserted inside an 
electrode module and was placed in the buffer tank along with an ice cooling 
unit (stored in -20 oC). The buffer tank was filled with transfer buffer (25 mM 
Tris, 0.2 mM Glycine, 20% v/v methanol, pH 8.3). The protein transfer was 
performed at 100 V for 2 hours at 4 oC (cold room). 
After the Western blotting step, in order to ensure the proteins had been 
transferred successfully, the nitrocellulose membrane (blot) was removed from 
the cassette and stained in 0.1% w/v Ponceau S 5% v/v acetic acid (Sigma, 
U.K.) for 2 minutes. Then the membrane was washed quickly with water for 4-
5 minutes. In the case of primary antibodies (HER2, β-actin and GAPDH) from 
Abcam company, the blot was blocked using 5% w/v BSA in PBST buffer 
(0.1% Tween 20 in PBS) for 1 hour at room temperature, while for the primary 
antibodies supplied by Cell Signalling Technology (CST), 5% w/v milk protein 
PBST was recommended by the manufacturer. After blocking, the blot was 
washed with PBST buffer three times for 5 minutes and incubated in the 
dilution of primary antibody recommended by the manufacturer in a 5% w/v 
BSA in PBST at 4 oC, gently rocking overnight. The blot was washed three 
times for 5 minutes each with 15 mL with PBST and incubated with the loading 
control (in this study anti-GAPDH and anti-beta Actin antibodies (Abcam, U.K.) 




minutes each with 15 mL with PBST. The blot was incubated with secondary 
antibody (Goat anti-rabbit IgG conjugated with HRP) diluted (1/5000) in 5% 
w/v skimmed milk powder in PBST (if the primary ab was from CST) or 5% w/v 
BSA in PBST (if the primary ab was from Abcam) for 1 hour, gently rocking at 
room temperature. The blot was washed three times for 5 minutes each with 
15 mL with PBST. Before starting the detection procedure, the blots were 
stored in PBS to avoid dehydration. The enhanced chemiluminescent (ECL) 
detection system (Thermofisher, USA) was used to detect the antibody-protein 
binding. Super Signal West Femto Trial Kit (Thermo scientific, USA) was used 
for this purpose. A working solution was prepared by mixing 1:1 ratio of the 
two reagents included in the kit (Luminol/Enhancer and Stable Peroxide 
Buffer). The mixture was added on the blot and incubated for 5 minutes. The 
remaining solution was absorbed by blue tissue and the blot was visualised 
using the Biospectrum Imaging System called UVP camera.  
 
2.2.9  Gene expression analysis 
 
For studying gene expression levels in the samples using qPCR method, ini-
tially cells were collected as a pellet, RNA was extracted, and mRNA was re-
verse transcribed into complementary DNA (cDNA).   
 
2.2.9.1  RNA extraction  
 
The cells cultured under different conditions were harvested with the 
procedures described previously in section 2.2.3. Total RNA was extracted 
using RNeasy Micro kit (Qiagen, Germany) according to the manufacturer’s 
instructions. In brief, 350 µL buffer RLT was added to the cell pellet and 
homogenized by pipetting. One volume of 70% v/v ethanol was added to the 




MinElute spin column (included in the kit and stored at 4 oC) and centrifuging 
for 15 secs at 13,000 RPM. The flow-through was discarded and 350 µL buffer 
RW1 was added to the column, centrifuging for 15 secs at 13,000 RPM. The 
flow-through was discarded and a mixture containing 10 µL of DNase I stock 
solution and 70 µL of buffer RDD (both included in the kit) was added directly 
to the RNeasy MinElute spin column membrane. The column was placed on 
the bench top at room temperature for 15 minutes. 350 μL buffer RW1 was 
added to the column and centrifuged for 15 sec at 13,000 RPM. The collection 
tube was discarded, and the column was housed in a new 2 mL collection 
tube. 500 μL Buffer RPE was added to the column and centrifuged for 15 sec 
at 13,000 RPM. The flow-through was discarded and 500 μL of previously 
prepared 80% v/v ethanol was added to the column. The column was 
centrifuged for 2 minutes at 13,000 RPM.  The collection tube was discarded, 
and column was placed in a new 2 mL collection tube. The column was 
centrifuged for 5 min to dry the membrane. The flow-through and collection 
tube were discarded, and column was placed in a new sterile 1.5 mL collection 
tube. 20 μL RNase-free water was added directly to the centre of the spin 
column membrane. The spin column was centrifuged for 1 min at 13,000 RPM. 
All steps were performed using a Pico 17 centrifuge (Thermo scientific, USA) 
and at room temperature.  
 
2.2.9.2  Evaluation of RNA integrity and purity 
 
The concentration of total RNA was measured using a Nanodrop spectropho-
tometer (Thermofisher Scientific, USA) at 260/280 nm. The RNA integrity was 
evaluated by separation of the RNA using a 1% w/v agarose gel prepared in-
house; 0.5 g agarose in 50 mL TBE buffer (10.8 g Tris, 5.5 g boric acid and 4 
mL 0.5 M NaEDTA, pH 8.0 in 1 litre water). RNA samples were mixed with 6 
X loading buffer (BioLabs, U.K.) and 6 µL of the mixture was loaded on the 
gel. 7 µL of 1Kb DNA ladder (BioLabs, U.K.) was used to estimate the base 




(Bio-Rad, U.K.) filled with TBE buffer and electrophoresed at 120 V for 1 hour 
with the Gel Red dye system and visualised using UV light (Appendix 3).  
 
2.2.9.3  Reverse transcription of mRNA to complementary 
DNA (cDNA) 
 
The mRNA was reverse transcribed into complementary DNA (cDNA) using 
the QuantiTect Reverse Transcription Kit (Qiagen, Germany) according to the 
manufacturer’s instructions. Briefly, 1 µg RNA was used for the preparation of 
each of the cDNA libraries. In the case of samples with lower amounts of RNA, 
500 ng RNA was used. In an Eppendorf tube, the RNA was mixed with 2 µL 
of gDNA (genomic DNA) wipe-out reagent and the volume were adjusted to 
14 µL with RNase free water. The mixture was incubated on a dry bath (Bio-
Rad, U.K.) at 42 oC for 2 minutes. A mixture of 1 µL reverse transcriptase (RT) 
enzyme, 4 µL of buffer and 1 µL of primer mix was prepared and added to the 
tube containing RNA, mixed by pipetting and incubated at 42 oC for 15 
minutes. To stop the reaction (deactivating the RT enzyme), the tube was in-
cubated at 95oC for 3 minutes. cDNA was stored at -80 oC freezer for future 
use.  
 
2.2.9.4  Quantitative polymerase reaction chain qPCR 
 
The cDNA library was used for the relative quantification of expression of EMT-
related genes including vimentin, snail1, cadherin-11, MMP14, apoptotic 
markers including Caspase 3, Caspase 9 and BCL2 and hypoxia marker 
including HIF1α and proliferation marker Ki67. The primer efficiency was 
assessed for each primer pair using the known concentrations of cDNA. The 
standard curve and R2 values obtained from primer efficiency tests. The 
reaction tubes were prepared using Quanti-Nova SYBR Green kit (Qiagen) 




tube with final volume of 20 µL, 4 µL of cDNA, containing 40 ng, 4 µL molecular 
biology grade water (Fisher Scientific, USA), 1 µL of 10 pmol/µL concentrated 
forward and reverse primer, and 4 µL of water was added into the sterile PCR 
tube. When the number of sample were more than 36, strip tubes 
(Qiagen,U.K.) were used. Negative controls were used in every run of qPCR: 
non-template control (NTC) and –RT controls (prepared by omitting the 
reverse transcriptase step during the preparation of the cDNA library). The 
tubes were placed in Rotor Gene real-time cycler (Qiagen, Germany) and 
cycling program was set as shown in Table 6. The sequences of the forward 
and reverse primers for the genes studied in this project are listed in table 7. 
The expression levels of GAPDH and β-actin, as an endogenous control gene, 
was measured in all samples in order to normalise input amounts. qPCR 
product sizes were estimated using the NCBI data base (Primer BLAST) and 





 Step Time Temperature  
PCR initial heat activa-
tion 
2 min 95oC 
2 step cycling 
Denaturation 5 sec 95oC 
Combined anneal-
ing/extension 
10 sec 60oC 
 
Number of cycles 40 






Gene Forward primer Reverse primer 















BCL2 TCGCCCTGTGGATGACTGA CAGAGACAGCCAGGAGAAATCA 
Ki67 CCACACTGTGTCGTCGTTTG CCGTGCGCTTATCCATTCA 
HIF-1α CGTTCCTTCGATCAGTTGTC TCAGTGGTGGCAGTGGTAGT 
β-Actin CTGTGGCATCCACGAAACTA CGCTCAGGAGGAGCAATG 
Table 7. List of primer sequences used for qRT-PCR. 
 
2.2.10 Alamar blue cell viability assay 
 
When cells are alive, they maintain a reducing environment in the cytosol. 
Resazurin (MW= 229 g/mol), the main compound in Alamar blue reagent is a 
non-toxic, cell permeable dye, blue in colour and non-fluorescent.  Following 
entry into the cells Alamar blue reagent is reduced to Resorufin, a red highly 
fluorescent component. MDA-MB231 and SKBR3 cells were cultured at a 
density of 5 x 104 cells per ACM/well for 3D culture and 3 x 104 for 2D 




blue assay according to the manufacturer’s protocol (Invitrogen). In brief, a 
10% v/v solution of Alamar blue in phenol and FBS free media was added to 
each well. For the negative control, the solution was also added to the wells 
without cells. Then plate was placed in the incubator at 37 oC, 5% CO2 for 4 
hours. The optimum incubation time and cell number had been determined 
beforehand. The absorbance values were measure using microplate reader 
(BMG, Labtech, U.K.) at a wavelength of 570 nm and 600 nm to calculate the 




                                                                      (Eoxi600 × A570) – (Eoxi570 × A600)    
                                                                      (Ered570 × C600) – (Ered600 × C570) 
 
Eoxi 570 = molar extinction coefficient (E) of oxidized Alamar blue Reagent at 
570nm =80586 
Eoxi 600 = E of oxidized Alamar blue Reagent at 600nm = 117216 
A 570 = absorbance of test wells at 570nm 
A 600 = absorbance of test wells at 600nm 
Ered 570 = E of reduced Alamar blue at 570nm = 155677 
Ered 600 = E of reduced Alamar blue at 600nm = 14652 
C 570 = absorbance of negative control well (media, Alamar blue reagent, no 
cells) at 570nm 
C 600 = absorbance of negative control well (media, Alamar blue reagent, no 
cells) at 600nm 
 
 




2.2.11 Drug treatment in 2D and 3D 
 
SKBR3 and MDA-MB231 cells cultured in 2D and 3D conditions were treated 
with doxorubicin (a DNA-damaging chemotherapeutic drug, MW= 543 g/mol). 
For 2D monolayer experiments, first, cells were seeded at the density of 3 x 
104 and grown overnight. Cells were serum starved with 2% v/v FBS DMEM 
for 24 hours before treatment.  For 3D culture, 5 x 104 cells were seeded in 
each gel for the two cell lines. Cells were allowed to acclimatize to the new 
environment and to form cell clusters for 5 days prior to serum-starvation.  To 
find the best concentration of the drug for treatment, cells were treated with 
different concentrations of doxorubicin (20 µM, 10 µM, 5 µM, 1 µM and 0.5 
µM) diluted in serum-free DMEM for 48 hours. Controls were treated with 
serum free DMEM only. The Alamar blue assay was used to assess cell 
viability after doxorubicin treatment. In order to compare drug response in 
static and dynamic conditions the concentration of 5 µM doxorubicin was 
selected for the treatment of cells in ACM. For each experiment, eight ACMs 
were constructed and maintained in static conditions for five days to allow cells 
to acclimatise to the 3D environment. Then, four ACMs were transferred to the 
Quasi Vivo chambers, and a flow of 550 µL/min of media was applied. Two 
separate systems of two-chamber Quasi Vivo with separate reservoir bottles 
were used in order to keep untreated and treated ACMs separate and under 
the same flow condition.  For static condition, 2 ACMs were treated and 2 were 
kept as untreated controls.   
 Statistical Tests 
Statistical analysis was performed using paired t-test when comparing mRNA 
expression of the genes and the cell viability in different culture conditions. a 
P-value of less than 0.05 was considered statistically significant. At least three 
dynamic experiments and three static controls were performed per flow rate 
for viability tests. Origin Lab software was used for analysing all the data and 
































3.1 Viability of cancer cells cultured in 2D and 3D 
MDA-MB231 and SKBR3 cells were cultured as 2D monolayers and in 
collagen type-I as ACMs, as shown in Figure 9, below. Since the space for 
cells cultured in 2D was limited to the well surface, fewer cells were initially 
seeded in the 2D cultures (20,000 cells/well) compared to 3D cultures (50,000 
cells/ACM).  
The viability of MDA-MB231 and SKBR3 cells cultured in the ACM with 
collagen type-I was compared, over a 7-day time course, with cells from the 
same passage number of cells cultured in 2D monolayer. The percentage 
reduction of the Alamar blue reagent was calculated and considered as a 
surrogate measure of the percentage of cell viability, Figure 10. 
The metabolic activity of SKBR3 cells cultured in both 2D and 3D increased 
after 3 days. However, the rate of increase in metabolic activity was lower in 
3D cell culture compared with 2D (not statistically significant). After 7 days the 
metabolic activity of cells decreased from 95% to 70% when the cells were 
cultured in 3D but in contrast, the metabolic activity increased slightly from 
72% to 80% in cells grown in 2D culture. The results illustrated that SKBR3 
cells were less metabolically active when grown in 3D cell culture compared 
to 2D monolayers. In contrast, when MDA-MB231 cells were grown in 2D 
compared with 3D they exhibited a 75% and 30% increase respectively 
(P<0.05). The metabolic activity of MDA-MB231 cells continued to increase by 
21% in 2D and 7% in 3D conditions until day 7 (P< 0.05). Overall, the results 
demonstrated that MDA-MB231 and SKBR3 cells were less metabolically 
































































































































































































































































































































































































































































































































































































Figure 10. reduction of alamar blue reagent indicating the metabolic activity 
of MDA-MB231 and SKBR3 cells grown over a 7-day period in 2D or in 3D 
(ACM). Overall, the rate of increase in metabolic activity reduced in both cells 




3.2 Ki67 mRNA expression in 2D and 3D cell culture 
 
To check if the results obtained in the cell viability assays (described above) 
were associated with changes in cell proliferation or metabolic activity the 
expression levels of a cell proliferation marker, Ki67, was assessed. Relative 
quantification of Ki67 mRNA levels for cells grown in 2D monolayers, 3D 
cultures embedded in collagen type-I (ACM) and without collagen (spheroids) 
for a week, was assessed using qRT-PCR. Gene expression levels were 
calculated for all samples and the levels were compared to cells cultured in 2D 
(control). GAPDH was used as the internal reference gene to normalize the 
cycle threshold (Ct) values of the mRNA. Three biological repeats were 
conducted, Figure 11.  
A significant decrease in Ki67 mRNA expression-levels were observed in both 
cell lines when they were cultured in collagen type-I in 3D (ACM) compared to 
2D conditions, figure 11. MDA-MB231 cells exhibited a 0.33 fold and SKBR3 
cells exhibited a 0.35 fold reduction in Ki67 mRNAs level when grown as ACM 
compared with 2D cell culture. In contrast, when cells were grown as spheroids 
there was a significant increase in relative gene expression for Ki67: MDA-
MB231 exhibited a 1.5 fold increase and SKBR3 exhibited a 2 fold increase in 
Ki67 mRNA compared to the control 2D culture.  These results demonstrate 
that cancer cells proliferation is affected by the microenvironment and cells 
grown as spheroids express more Ki67 compared with cells grown in contact 




                            
Figure 11. Quantification of Ki67 mRNA expression level in MDA-MB231 and 
SKBR3 cells cultured in 3D (ACM) and 3D (spheroid) relative to 2D culture. 
Ki67 mRNA level increased significantly when cells were cultured as spheroids 
compared to 2D culture. However, its expression decreased significantly when 
cells were grown in collagen matrix (ACM). The experiment was performed 
using quantitative real time PCR technique and mRNA expression levels were 
normalised with GAPDH as reference ΔΔCT was calculated by subtracting 
ΔCT 2D culture (control) from ΔCT of each culture condition. R= 2^-ΔΔCT, 
corresponds to the fold change. Data presented is mean average ± SD (n = 
3). Asterisks denote significant differences in gene expression, paired 
Student’s t-test; ∗P <0.05; ∗∗P<0.01; ∗∗∗P<0.001 
3.3 Investigating hypoxia status by measuring HIF-1α mRNA 
expression 
To investigate if the growth of MDA-MB231 and SKBR3 cells in 3D culture 
format (with and without ECM) can generate a hypoxic environment, the 
mRNA expression level of HIF-1α was measured using qPCR.  
HIF-1α is an oxygen sensitive subunit of HIF-1 protein and its expression is 
induced under hypoxic conditions. The relative gene expression was 




with gene expression normalised to GAPDH as an internal reference gene. 
The data have been obtained from three experiments performed in triplicate, 
Figure 12, There was no significant difference between HIF-1α mRNA level of 
MDA-MB231 cells cultured in ACMs compared to that for cells cultured in 2D.  
HIF-1α levels in SKBR3 cells was significantly increased, in ACM conditions. 
However, growing both cell lines as spheroid resulted in significant increase in 
HIF-1α mRNA level with 7 fold and 37 fold increase in MDA-MB231 and 
SKBR3 cells respectively.  
 
Figure 12. Quantification of HIF-1α mRNA expression levels in MDA-MB231 
and SKBR3 cells cultured in ACM and spheroid relative to its level in 2D culture 
after a week. HIF-1α mRNA expression level increased significantly when both 
cells grown in spheroid format compard to 2D culture. Its expression also in-
creased significantly when SKBR3 cells cultured in collagen matrix. The ex-
periment was performed using quantitative real time PCR technique and 
mRNA expression levels were normalised with reference to GAPDH. ΔΔCT 
was calculated by subtracting ΔCT 2D culture (control) from ΔCT of each cul-
ture condition. R= 2^-ΔΔCT, corresponds to the fold change. Data presented 
are mean average values ± SD (n=3). Asterisks denote significant differences 





3.3 EMT mRNA expression levels in MDA-MB231 
 
In this part of study, the aim was to investigate if maintaining cells in 3D culture, 
ACM and spheroid, affects the EMT status of MDA-MB231 cells. Since 
expression levels of the selected EMT marker genes were too low in SKBR3 
cells, they were excluded from this part of study. Accordingly, qRT-PCR was 
used to assess the levels of mesenchymal cell markers: snail, Cadherin-11, 
Vimentin and MMP14 (MT1-MMP) for cells grown in 2D, and in 3D as ACM 
and spheroids for 7 days. Relative gene expression was determined for 
samples grown in 3D compared with those grown in 2D in relation to control 
samples (MDA-MB cells cultured in 2D) and corrected to Ct values of the 
housekeeping gene (GAPDH). The data has been obtained from three 
experiments performed in triplicate, Figure 13.  
Although the vimentin mRNA level was shown to be slightly higher in both 3D 
cultures compared to 2D condition, no significant difference between the 3 
samples (3 culture conditions) was evident.  
Different trends were observed in results obtained from analysing MMP14 and 
snail1 mRNA expression level in MDA-MB231 cells. Compared to 2D culture, 
MMP14 mRNA level increased significantly by 2 folds in ACM and 3 folds in 
spheroid. A significant elevation in snail1 expression was also observed, with 
2.7 (ACM) and 3 (spheroid) folds increase compared to 2D condition.  
In contrast, a significant reduction (75%) in Cadherin-11 mRNA level was 
observed in MDA-MB231 cells cultured in (ACM) compared to the cells in 2D. 
However, when cells were grown as spheroids, Cadherin-11 mRNA level 
increased significantly by 5-fold. These results suggest that 3D 
microenvironment may induce the expression of MMP14 and snail 1 genes 
regardless of ECM presence and that vimentin expression was less affected 
by altering the microenvironment. In contrast, different microenvironments and 





Figure 13. Quantification of expression level of the genes involved in EMT in 
MDA-MB231 cells cultured in 3D (ACM) and 3D (spheroid) relative to 2D cul-
ture. The expression levels of MMP14, snail and cadherin 11 increased signif-
icantly when cells were grown as spheroid. The mRNA expression of MMP14 
and snail 1 also increased in cells grown in collagen matrix while cadherin 11 
expression showed a significant reduction compared to 2D condition. Vimentin 
mRNA expression increased slightly in 3D spheroid and ACM culture com-
pared to 2D condition (non-significant). The experiment was performed using 
quantitative real time PCR technique and mRNA expression levels were nor-
malised against GAPDH. ΔΔCT was calculated by subtracting ΔCT 2D culture 
(control) from ΔCT of each culture condition. R= 2^-ΔΔCT, corresponds to the 
fold change. Data presented are mean average values ± SD (n=3). 
3.4 Western blot analysis and immunostaining for vimentin 
protein in MDA-MB231 cells 
 
To confirm the results obtained from qRT-PCR analysis of vimentin in MDA-
MB231, the protein level was assessed using Western blot analysis. Since 
ACMs were selected as 3D model to be used in the next step of the project 
(applying flow), only ACM (using collagen type-I) were selected to be assessed 
in this regard. The MDA-MB231 cells cultured in 3D (ACM) conditions were 




The total protein concentration was measured using BCA assay and 10 µg of 
total protein from each sample (2D and 3D) was separated using SDS-PAGE 
and probed against vimentin antibodies after being transferred to nitrocellulose 
membrane. An anti-GAPDH antibody was used as a reference protein (loading 
control).  Secondary antibody conjugated with HRP was used to detect primary 
antibodies bonded to the proteins on nitrocellulose paper and an enhanced 
chemiluminescence reaction system was used to detect the bands.  
Additionally, immunostaining experiments were performed to confirm the 
presence and distribution of target proteins in cells. Since the cells were 
embedded in collagen, the staining protocol followed for cells in ACM was 
slightly different from that used for cells in 2D culture. 
The western blot result is shown in Figure 14(a). The vimentin protein was 
present in increased levels in MDA-MB231 cells grown in 3D (ACM) compared 
to those grown in 2D for 2 weeks. Since the anti-vimentin antibody used in 
western blot was against phosphorylated and non-phosphorylated types of 
vimentin, we assumed that the observed two bands correspond to 
phosphorylated and non-phosphorylated forms of vimentin. As can be seen in 
the Western blot result, the relative amounts of phosphorylated vimentin are 
increased in cells cultured in collagen (ACM) compared with cells cultured in 
2D. This result suggested that although vimentin mRNA levels in 2D and 3D 
culture were not predominantly different, more vimentin filaments become 
phosphorylated through post translational modifications when the cancer cells 
are grown as 3D (ACM). Vimentin phosphorylation can lead to disassembly of 
vimentin filaments which increases cancer cell motility and invasion (Yasui et 
al., 2001). Vimentin protein levels were confirmed by images obtained from 
immunostaining of MDA-MB231 cells cultured in 2D and 3D for 2 weeks. 
Although different fluorescent microscopes were used due to limitations in the 
confocal microscopy apparatus, the images of the cell aggregates show that 
MDA-MB231 cells express almost the same amount of vimentin protein in their 
cytosol as they present in 2D, Figure 14 (b). 





                                                  
 
 
               
             
















































































































































































































































































































































































































































































































































































































































































































3.5 Expression of HER2 in SKBR3 cells cultured in 2D and 3D 
 
As described earlier, SKBR3 cells are highly positive for HER2 expression. To 
investigate the impact of different culture conditions on the level of HER2 
mRNA expression, RNA was extracted from SKBR3 cells grown in 2D, ACM 
and spheroid for a week Then, cDNA was prepared using reverse 
transcriptase kit and qPCR reactions performed. Relative to the 2D culture 
method, the HER2 mRNA level was higher by 1.3- and 1.7-fold when cells 
were grown as ACM and spheroid respectively, Figure 15. However, only 
spheroid culture conditions resulted in a statistically significant difference in 
gene expression, (p<0.05). 
 
 
Figure 15. Quantification of HER2 mRNA expression in SKBR3 cells cultured 
as ACM and spheroid relative to its expression in cells grown in 2D condition. 
HER2 expression increased significantly in cells grown as spheroid and ACM 
compared to 2D culture. The experiment was performed using quantitative real 
time PCR and mRNA expression levels normalised against GAPDH. ΔΔCT 
was calculated by subtracting ΔCT 2D culture (control) from ΔCT of each cul-
ture condition. R= 2^-ΔΔCT, corresponds to the fold change. Data presented: 




3.6 Western blot analysis and immunostaining of HER2 
protein in SKBR3 cells 
 
To confirm the results of the HER2 expression analysis obtained using the 
qPCR technique, the HER2 protein levels of SKBR3 cells cultured in 2D and 
3D (ACM) was measured using Western blot and immunostaining assays. For 
HER2 Western blot analysis, SKBR3 cells were not treated with collagenase 
to avoid loss of HER2 from cell membrane. The ACMs were disrupted using 
lysis buffer (RIPA buffer) added to two pooled ACMs and a homogeniser (T25 
digital Ultra-Turrax, U.K.). The anti-GAPDH antibody was used as loading 
control. The HER2 protein levels were slightly higher when the cells were 
cultured in collagen type-I as ACMs compared with 2D, Figure 16. However, 
the bands showing higher molecular weight indicate higher levels of 
phosphorylated HER2 compared to non-phosphorylated HER2 in both 2D and 
3D cultured cells.  
In addition to the results of the Western blot analysis, microscopy images 
taken following immunostaining of SKBR3 cells using the anti-HER2 antibody 
indicated the presence of HER2 protein in the cell membrane of the cells 











                                        
Figure 16. HER2 protein level in SKBR3 cells grown in 2D and 3D (ACM) 
condition. Panel a) Western blot analysis of HER2 protein in SKBR3 cells 
grown as 2D or 3D (ACM) cultures. 10 µg protein was loaded in each well. 
GAPDH antibody was used as loading control. Panel b) Immunofluorescent 
staining of SKBR3 using HER2 antibody. Left picture, taken using confocal 
microscopy, shows SKBR3 cells grown in 2D and stained with To-Pro-3 (blue) 
and HER2 antibody (green). The middle image shows SKBR3 cell aggregates 
in ACM imaged using confocal microscope. The right image, taken using Zeiss 
Apo Tom 0.2 fluorescent microscope, shows SKBR3 cells grown in ACM and 
stained with DAPI (blue) and anti-HER2 antibody (green). The images 
indicated the presence of HER2 protein in SKBR3 cells cultured in 2D and 3D 
collagen matrix. Representative images taken from n=2 experiments imaged 





3.7 mRNA expression of apoptosis-related genes 
 
To investigate if apoptotic changes occurred in MDA-MB231 and SKBR3 cells 
cultured in 3D (ACM), qPCR analysis was performed focusing on a panel of 
three apoptosis related genes including caspase 3, caspase 9 and BCL2. The 
transcriptional expression levels of BCL2, an anti-apoptosis factor, was 
significantly upregulated in MDA-MB231 cells grown in ACM, with a 5-fold 
increase compared to 2D conditions, Figure 17. However, no significant 
difference was observed in the mRNA expression levels of the proapoptotic 
markers caspase -3 and caspase -9 when MDA-MB231 cells were cultured in 
3D.  There was a reduction in the mRNA level of these proapoptotic genes in 
SKBR3 cells cultured in 3D (ACM) while a significant 1.4-fold increase was 
observed in BCL2 mRNA levels was observed in these cells.  These results 
suggest that 3D collagen microenvironment do not induce the expression of 
pro-apoptotic markers in SKBR3 and MDA-MB231 cells. However, this 











Figure 17. Relative quantification of apoptosis related genes in MDA-MB231 
and SKBR3 cells cultured in 2D and 3D. The results indicated that BCL2 anti-
apoptotic gene was upregulated in both cells when they were grown in 3D 
(ACM) condition compared to 2D condition. Transcriptional expression of 
indicated genes was measured by real-time qPCR. mRNA expression levels 
were normalised against GAPDH. ΔΔCT was calculated by subtracting ΔCT 
2D culture (control) from ΔCT of each culture condition. R= 2^-ΔΔCT, 
corresponds to the fold change. Data were presented are mean average ± SD 




3.8 Efficacy of doxorubicin in 2D and 3D culture 
 
To investigate if 3D culture and the microenvironment surrounding the cancer 
cells affected the cytotoxicity of doxorubicin, viability of the cells cultured in 2D 
and 3D (ACM) was measured after doxorubicin treatment using Alamar blue 
assay. To find out the appropriate concentration of doxorubicin for treating 
breast cancer cells in the next phase of study (comparing static and dynamic 
culture conditions), cells grown in 2D and 3D culture were treated with different 
concentrations of doxorubicin.   
MDA-MB231 cells were insensitive to lower concentrations of doxorubicin (0.1 
µM and 0.5 µM) in both culture conditions while they responded to 1 µM 
doxorubicin only in 2D culture. However, when MDA-MB231 cells were grown 
in 3D conditions they were significantly less sensitive to doxorubicin at 
concentrations of 5 µM and 10 µM compared to those grown in 2D, with 
increase in cell viability from 30% to 70% in concentration of 5 µM and from 
28% to 65% in concentration of 10 µM, Figure 18. SKBR3 cells grown in 2D, 
showed a dose dependant decrease in cell viability in response to doxorubicin 
treatment, Figure 18. As observed with the MDA-MB231 cells, SKBR3 cells 
showed least sensitivity to lower concentrations (0.1 µM and 0.5 µM) of 
doxorubicin.  However, SKBR3 cells grown in both 2D and 3D, appeared to 
responsd to doxorubicin at concentrations of 5µM and 10µM. The viability of 
the cells treated with 5 µM doxorubicin appeared to be significantly (2.3 fold, 
p<0.01) greater in the cells grown in 3D compared to those in 2D. Also, at 
concentration of 10 µM, the percent viability in SKBR3 cells grown in 3D 
culture appeared to be significantly (~1.6-fold, P <0.01) higher than those 
grown in 2D monolayer format.   
Collectively, the results obtained from this part of project showed that both cell 
lines appeared to be more resistant to doxorubicin when cells cultured in ECM 





Figure 18. The cytotoxic effect of doxorubicin on MDA-MB231 and SKBR3 
cells cultured in 2D and 3D. Both cell types showed less sensitivity to specific 
concentrations of doxorubicin when they were grown in 3D collagen matrix 
(ACM) compared to 2D condition. Three wells were assessed for each 





3.9 Cell aggregates and invasion bodies formed in static and 
flow/pressure conditions 
 
The cancer cells were grown in collagen type-I using RAFT system (ACM) and 
were maintained in static and flow/pressure conditions for two weeks (MDA-
MB231) and one week (SKBR3). The formation of cell aggregates and 
invasion bodies were monitored using light microscopy and fluorescent 
microscopy (by staining only nuclei). To observe the number of cells in each 
aggregate, the nuclei of the cells in ACMs were stained with DAPI and imaged 
by the Apo Tom 0.2 microscope. Figure 19 shows a monochrome image of 
DAPI staining of the ACMs of both cell lines in static and flow/pressure 
conditions. As can be seen in Figure 19, left panel, from observing the nuclei 
of the MDA-MB231 ACMs, they formed more structured mass-shaped clusters 
whilst a grape-like morphology was adopted by the cells cultured under flow 
and pressure.  Also, flow/pressure was associated with lower number of cells 
in MDA-MB231 cell aggregates compared to static condition. 
When comparing the overall distribution of cancer cells in ACMs maintained in 
static and dynamic condition for a month, MDA-MB231 cells were dispersed 
more evenly over the ACM area while the shape of the invasion bodies -
protrusion of cancer cells from the centre of ACM to the surrounding collagen 
- were more organised in static conditions, whereas in the presence of flow 
and pressure, cell protrusion was disorganised, and the edges were more 
jagged. In the case of SKBR3, no difference between the ACMs was noticed.  
The size of SKBR3 cell aggregates and the number of cells in each cluster 
were not different in ACMs maintained in static and flow/pressure Figure 19, 
right panel. Also, comparing the two cell lines, SKBR3 cells formed smaller 
aggregates compared to MDA-MB231 cells. Also, the same distribution of 
SKBR3 cells in ACMs maintained in static and flow/pressure conditions was 
observed after a week. Overall, these results suggest that different breast 
cancer cells may react to changes in the fluid dynamics within their 



























































































































































































































































































































































































































































































































































































3.10 Comparing cell viability of cancer cells in static and 
flow/ pressure 
To investigate the effect of flow and pressure on cell viability of cancer cells, 
MDA-MB231 and SKBR3 cells cultured in 3D RAFT system (ACMs) were 
maintained under static and flow/ pressure (flow of 550 µL/min and pressure 
of ~19 mmHg) conditions for 14 (MDA-MB231) and 7 (SKBR3) days. Two 
ACMs were used for each condition. For the cells grown under static 
conditions, half of the media was replaced with fresh media every other day 
and for those grown in flow, this was done every 4 days due to the higher 
volume of the media (20 mL) that needed to run the Quasi Vivo system. Cell 
viability was measured using Alamar blue assay at three-time points: a day 
after constructing the ACMs (day 1), day 7 and 14 (for MDA-MB231 cells only).  
As shown in Figure 21, the viability of MDA-MB231 cells maintained under 
flow/ pressure appeared to be less than those maintained in the static 
condition over a 14-days period. On the first day, all ACMs showed the same 
level of cell viability indicating that the cell density was the same in all ACMs 
before putting them under different conditions (static and flow + pressure).  
After 7 days, the viability of the cells in static condition increased by 50% while 
those grown in the flow /pressure condition, increased by only 15%, indicating 
a significant decrease in cell viability in flow/pressure system (P <0.05). 
However, the same increase gradient was observed in both conditions 
between 7th and 14th days, with only a 3.2% increase for both conditions. 
Overall, MDA-MB231 cells exhibited a 30% decrease in cell viability when 






Figure 21. The effect of fluid flow and pressure on cell viability when cells are 
grown in 3D under static and flow conditions, measured by Alamar blue assay.  
Upper graph, MDA-MB231 cells grown over a 14-day, bottom graph, SKBR3 
grown over a 7-day period. Both cell types were less metabolically active in 
the presence of flow and pressure compared to static condition. Data 






Since the cellular viability of SKBR3 cells grown in 3D and flow + pressure 
conditions decreased considerably after a week, the Alamar blue assay was 
performed only on days 1 and 7. Four ACMs were formed using RAFT system 
and 2 ACMs were allocated to each condition. Cell viability was measured at 
day 1 after seeding was slightly different in each condition.  
Cells grown under the static conditions demonstrated a 20% increase in cell 
viability while those cultured under flow/ pressure exhibited no increase in cell 
viability, but surprisingly their viability fell by 58% compared to first day. In 
general, these results indicate that SKBR3 cells cultured in 3D (ACMs) and 
flow condition are significantly (P <0.05) less viable compared to those grown 
in 3D/static condition.  
 
3.11 Ki67 mRNA expression level in the cancer cells cultured 
in static and dynamic conditions 
 
Metabolic (oxidation-reduction) reactions maintain a reduced environment in 
the  cell’s cytosol which can reduce Alamar blue reagent and change its colour 
from blue to pink. Given this fact, any change in percentage of reduction of 
Alamar blue reagent can be either due to alteration in cell proliferation and 
growth or changes in the metabolic activity of the cells themselves. To identify 
if cells cultured under static and flow/pressure conditions differ in terms of cell 
proliferation, Ki67 expression levels were measured using qPCR.  In both 
conditions, 3D static and flow/pressure, cells exhibited lower expression levels 
of Ki67 compared to when they were cultured on 2D surfaces (Appendix 4). 
However, comparing static and flow/pressure conditions, there was a 
significant (P<0.01) increase in Ki67 mRNA expression levels in the cells (both 
cell lines) maintained in flow/pressure compared to those grown in static 
condition. Figure 22  The Ki67 expression level increased by 1.31 and 1.33 
fold in MDA-MB231 and SKBR3 cells respectively, when they were grown 




results indicated that the dynamic environment (flow/pressure) increased 
expression of proliferation markers in MDA-MB231 and SKBR3 breast cancer 
cell lines.  Also, these results indicate that the decrease in metabolic activity, 
which was found in previous Alamar blue assay is not due to lower proliferation 
rate in cells cultured in flow but likely due to lower rate in metabolic reactions 





Figure 22. Relative quantification of Ki67 gene expression levels in MDA-
MB231 and SKBR3 cells cultured in static and flow/pressure conditions. Ki67 
mRNA level of both cell types increased significantly in the presence of flow 
and pressure compared to static condition. ΔΔCT was calculated by 
subtracting ΔCT 2D culture (control) from ΔCT of each culture condition. R= 






3.12 Hypoxia status of the cells grown in 3D/static and 
3D/dynamic conditions  
 
To investigate if flow and pressure might generate hypoxic conditions in cancer 
cells grown in 3D scaffolds (ACM), HIF-1α mRNA expression levels were 
measured in MDA-MB231 and SKBR3 cells grown in 3D and maintained under 
three different conditions: static, flow (150 µl/min) and flow/pressure (550 
µl/min, ~19mmHg), Figure 23. The R (fold change) (Schmittgen and Livak, 
2008), was calculated by considering cells cultured in static condition as the 
control group. A significant increase in expression of HIF1-α mRNA was 
observed in cells cultured in flow condition (2.2 fold) compared to those 
cultured in static condition. However, when ACMs were maintained under flow/ 
pressure conditions, there was no significant difference in HIF1-α expression. 
A similar pattern was observed in SKBR3 cells cultured in the different 
conditions. Flow was associated with a significant increase (1.8 fold, P <0.05) 
in HIF-1α gene expression whereas flow and pressure resulted in no 
significant difference in expression of this gene compared to the static 
condition. These results suggest that cells cultured under flow rate (of 150 
µL/min) may be under more hypoxic conditions compared to those cultured in 












Figure 23. Relative quantification of HIF-1α mRNA expression levels in MDA-
MB231 cells cultured in 3D static, 3D flow and 3D flow + pressure after 2 
weeks. HIF-1α expression increased significantly in flow condition compared 
to static condition however it remained unchanged in flow + pressure. The 
experiment was performed using quantitative real time PCR and mRNA 
expression levels were normalised against GAPDH. ΔΔCT was calculated by 
subtracting ΔCT static culture (control) from ΔCT of the other culture 
conditions. R= 2^-ΔΔCT, corresponds to the fold change. Data presented are 




3.13 EMT marker expression in MDA-MB231 cultured in static 
and dynamic conditions 
 
Having defined the effect of 3D culture and cell-ECM contacts on expression 
of mesenchymal markers in MDA-MB231 cells (section 3.5), the effect of flow 
and pressure on expression of these markers in MDA-MB231 cells cultured in 
3D (ACM) was evaluated. Six ACMs were constructed in 24-well plates and 
maintained at 37oC with 5% CO2 in static condition for one day. On day 2, two 
ACMs were kept in the static condition, two ACMs were transferred to flow 
(150 µL/min) and two ACMs were transferred to flow/pressure (550 µL/min & 
~19 mmHg) culture conditions.  After two weeks, the cells in all ACMs were 
collected and cDNA was prepared from extracted RNA. Cells grown in static 
were considered as control samples. Equal amounts of cDNA was used for 
qPCR analysis of the genes in all conditions.  
The 2D culture was considered as control and relative gene expression was 
calculated. There was generally an increase in gene expression for Vimentin, 
MMP14 and snail1 in MDA-MB231 cells cultured in 3D and maintained in all 
three conditions (static, flow and flow/pressure) relative to cells grown in 
conventional 2D monolayer culture. The only exception observed was the 
reduction of vimentin (40%) mRNA level in the cells cultured in flow/pressure. 
However, there was a 1.6 fold increase in its expression level when the ACMs 
maintained under flow of 150 µl/min (Appendix 5) As it was also shown in 
previous section (3.4) there was no significant increase in vimentin mRNA 
level when they grew in 3D/static compared to 2D condition. Figure 24 shows 
the mRNA expression of the three genes for MDA-MB231 cells grown in the 
dynamic condition relative to static condition. Vimentin expression increased 
by 1.7-fold (P<0.05) in the presence of flow and decreased by 0.7 (P<0.05) 
fold when flow/pressure was applied.  Analysis of MMP14 mRNA level in MDA-
MB231 cells cultured in flow and flow/pressure indicated a 1.5-fold increase in 
both conditions compared to static. These results show that presence of fluid 
flow and pressure in the microenvironment of MDA-MB231 cell growth, result 




expression level increased when MDA-MB231 cells were grown in flow 
compared to when grown in static conditions, with 2.5- fold increase (P<0.01). 
However, flow/pressure conditions appeared to have no effect on snail1 




Figure 24. Relative quantification of vimentin, MMP14 and snail1 mRNA 
expression levels in MDA-MB231 cells cultured in 3D/static, 3D/flow and 
3D/flow/pressure after 2 weeks. The experiment was performed using 
quantitative real time PCR technique and mRNA expression levels were 
normalised against GAPDH. ΔΔCT was calculated by subtracting ΔCT of static 
culture (control) from ΔCT of each culture condition. R= 2^-ΔΔCT, corresponds 







3.14 Western blot and immunostaining of vimentin protein in 
MDA-MB231 cells cultured in static and flow/pressure 
condition 
 
To confirm the results obtained from qRT-PCR analysis for vimentin in MDA-
MB231, the protein level of vimentin was assessed using Western blot. 
Additionally, immunostaining was performed to confirm the presence and the 
location of the proteins in the cells. The same staining protocol was followed 
for ACMs maintained in static and flow/pressure condition. The Western blot 
results of 2D and 3D conditions has been previously discussed in section 3.5. 
Figure 25 shows that the vimentin protein level significantly decreased in MDA-
MB231 cells grown in flow/pressure compared to those grown in static for 2 
weeks. Two bands correspond to phosphorylated and non-phosphorylated 
forms of vimentin. 
Vimentin protein level was confirmed by images obtained from 
immunostaining of MDA-MB231 cells cultured in static and flow/pressure for 2 
weeks. The images of cell aggregates showed that MDA-MB231 cells express 
lower amount of vimentin protein in their cytosol in static conditions (figure 
25b). Also, left panel of the images show that the amount of vimentin is lower 
in the edge of the ACMs (where the cells invade to the surrounding stroma) 



















































































































































































































































































































































































































































































































































































































































































3.15 Expression of HER2 in SKBR3 cells cultured in 3D/static 
and 3D/flow/pressure conditions 
 
As indicated in the previous chapter, HER2 mRNA level appeared to increase 
slightly as a result of cell-ECM interactions in the ACMs. To evaluate the effect 
of flow and pressure on HER2 expression of SKBR3 cells grown in ACM, 2 
ACMs were maintained under flow of 550 μL/min and pressure of ~19 mmHg 
in the Quasi Vivo system for a week. The cells were harvested from the ACMs 
and RNA was extracted to be used for cDNA preparation. SKBR3 cells with 
the same passage number cultured in 3D (ACM) were considered as control 
group in qRT-PCR analysis and calculation of R (fold change). As shown in 
Figure 26, HER2 mRNA expression increased by 2.4 fold in flow/pressure 
compared to static condition and the difference was significant (P <0.05).  The 
results suggest that SKBR3 cells express higher level of HER2 mRNA when 
they are grown under flow/ pressure conditions.  
 
Figure 26. Relative quantification of HER2 mRNA expression levels in SKBR3 
cells cultured in 3D static and 3D flow + pressure system after a week. The 
results indicated that HER2 expression upregulated in the presence of flow 
and pressure compared to static condition. The experiment was performed 
using quantitative real time PCR technique and mRNA expression levels were 
normalised against GAPDH. ΔΔCT was calculated by subtracting ΔCT static 
condition (control) from ΔCT of each culture condition. R= 2^-ΔΔCT, 




3.16 Immunostaining of SKBR3 cells against HER2 antibody 
 
Following qRT-PCR analysis for HER2 gene expression, ACMs maintained in 
static and flow/pressure were stained using the anti-HER2 antibody, Figure 
27. The fluorescent images obtained from the ACMs showed there was no 
significant difference between HER2 protein level in SKBR3 cells grown in 
3D/static vs those in 3D/flow/pressure conditions.    
   
3.17 mRNA expression of apoptosis-related genes in breast 
cancer cells cultured in 3D/static and 3D/dynamic 
conditions 
 
Relative quantification of caspase -3, caspase-9 and BCL2 genes was 
performed to investigate the effect of flow and pressure on expression of 
apoptosis-related genes in SKBR3 and MDA-MB231 cells. There was a 60% 
reduction in the expression of caspase 3 MDA-MB231 cells cultured in flow 
and pressure compared to static condition. In contrast, flow/pressure condition 
was associated with a significant increase of 13 fold in the expression of 
caspase 9 (P <0.05). Although not significant, expression of BCL2 reduced by 
almost 80% in flow and pressure compared to static condition, Figure 28.   
A significant increase in mRNA levels of caspase -3 and -9 was observed in 
SKBR3 cells grown in flow/pressure condition with 3.5 and 2.5 fold higher 
expression, respectively, compared to static condition. Overall, the results 
obtained indicated that introducing flow and pressure on breast cancer cells 
increases the expression of pro-apoptotic markers (caspase-3 and caspase -
9) and reduces the expression of the anti-apoptotic marker BCL2.  
 
 




                 
                                                   
































































































































































































































































































Figure 28. Quantification of apoptosis related genes in MDA-MB231 (top 
graph) and SKBR3 cells (bottom graph) cultured in flow + pressure condition 
relative to its level in static condition.  Caspase 9 mRNA expression increased 
and BCL2 decreased in both cell types suggesting induction of apoptosis in 
the presence of flow and pressure. Transcriptional expression of indicated 
genes was measured by real-time qPCR. mRNA expression levels were 
normalised against GAPDH. ΔΔCT was calculated by subtracting ΔCT of static 
(control) from ΔCT of each culture condition. R= 2^-ΔΔCT, corresponds to the 




3.18 Sensitivity to doxorubicin in breast cancer cells cultured 
in 3D/static and 3D/dynamic conditions 
 
Interstitial fluid flow (IFF) and interstitial fluid pressure (IFP) are also important 
components of the tumor microenvironment and is suggested to influence drug 
responsiveness of cancer cells. Cytotoxicity effect of doxorubicin on MDA-
MB231 and SKBR3 cells grown in collagen (ACM) and maintained in static or 
under different dynamic conditions in our Quasi Vivo system was assessed 
using the Alamar blue assay.  
As indicted in the methods section, all ACMs were prepared and maintained 
under static conditions for 5 days to allow cells to acclimatise to the new 
environment (collagen). On the day 5, the percentage of cell viability was 
measured in all ACMs to make sure the number of cells seeded in all ACMs 
was the same. Then, two ACMs were transferred to two Quasi Vivo systems 
(two in each system, one system for untreated controls and one system for 
treated ones). All ACMs including those in static and those in flow/pressure 
(550 µL/min and 19 mmHg) or only flow (150 µl/min) were serum starved for 
24 hours prior to being treated with 5 µM doxorubicin for 48 hours. A 5 µM 
concentration was selected according to the results obtained from the previous 
experiments on treating cells in 2D and 3D (ACM) using different 
concentrations of doxorubicin. The viability of the cells was measured using 
Alamar blue assay after 48 hours. 
The cytotoxicity of doxorubicin on the cells cultured in static condition was 
compared with those in flow/pressure conditions. Figure 29a indicates that low 
flow (150 µL/min) was associated with a 40% decrease in MDA-MB231 cell 
viability compared to the static condition (P <0.05). Likewise, treating MDA-
MB231 cells under flow and pressure conditions, maintained cell viability with 
a 36% enhancement compared to treating the cells in the static condition, 
figure 29b. As the result showed, figure 29c, SKBR3 cells were also more 
sensitive to doxorubicin treatment when they were grown in static compared 




they were grown in 3D/flow/pressure compared to 3D/static condition. These 
results suggest that flow and pressure in tumour microenvironment can affect 
cancer cell sensitivity to chemotherapeutic drugs. 
      





                                                   
                   
                        
Figure 29. Comparing the cytotoxic effect of doxorubicin on MDA-MB231 and 
SKBR3 cells grown in different conditions. a) Viability of MDA-MB231 ACMs 
maintained in 3D low flow with those in 3D static condition. b) Comparing 
viability of MDA-MB231 cells grown in flow/pressure with those grown in static. 
c) SKBR3 responses to doxorubicin treatment in flow + pressure and static 
conditions. The results indicated that the cells are less sensitive to doxorubicin 
treatment when they were grown in the dynamic (flow and pressure) condition 
compared to static condition. Two wells were assessed for each concentration 
and the result is from three experiments. 
3.19 Expression of EMT markers in presence of flow and 
normal fibroblasts 
 
In the final part of the project, the effects of fibroblast cells grown in 3D 
scaffolds (ACMs) on induction of EMT in the cancer cells were investigated 
under flow condition. The fibroblasts grown in a 24-well plate format RAFT gel 
and a cancer ACM were nested in a series chamber format designed so that 
the fibroblast chamber was next to the reservoir bottle. Another Quasi Vivo 
system having only one chamber (ACM) was also run in parallel as control. 




µL/min was applied for 7 days. The relative quantification of mRNA of EMT 
markers and Ki67 was performed using qRT-PCR. The initial results from a 
single experiment showed that MMP14 and snail mRNA expression increased 
in the presence of fibroblasts while the expression levels of vimentin and 
cadherin 11 slightly decreased and that the Ki67 mRNA level remained 
unchanged, Figure 30. However, these experiments require repeats for further 
validation. The results suggest that fibroblasts produce chemokines and 
factors that may affect the expression of the genes associated with ECM 





Figure 30. Relative quantification of vimentin, MMP14, snail1, cadherin 11 and 
Ki67 mRNA expression levels in MDA-MB231 cells cultured in 3D flow with 
and without fibroblasts after a week. MMP14 and snail1 mRNA expression 
increased in the presence of normal fibroblasts (NFs). The experiment was 
performed using quantitative real time PCR technique and mRNA expression 
levels were normalised against GAPDH. ΔΔCT was calculated by subtracting 




corresponds to the fold change. Data is presented as single experiment 
performed in triplicate. 
3.20 MDA-MB231 invasion in ACMs with and without normal 
fibroblasts 
 
To investigate if addition of normal breast-derived fibroblasts can affect cancer 
cell invasion, the fibroblast cells were embedded in the stromal collagen in the 
RAFT system. Three ACMs were imaged for each condition using an inverted 
light microscope after 7 days, Figure 31.  
The images indicate an increase in the number of cancer cells invading from 
tumour mass to the stroma where normal fibroblasts exist. The migration dis-
tance of the MDA-MB231 cells increased in the presence of fibroblasts. The 
results suggest that even normal breast-derived fibroblasts may affect the in-







                            
                            





































































































































































































































































































4.1 Breast cancer cell viability, proliferation and apoptosis 
 
The effect of different components of tumour microenvironment on cancer cells 
behaviour has been intensely studied (Wang et al., 2017, Anari et al., 2018). 
Since cell proliferation and growth are major causative factors in the 
development and the progression of cancer changes in these parameters 
have most often been assessed and in particular when cancer cells were 
exposed to different microenvironments. In this study the viability and 
proliferation of breast cancer cells was evaluated whilst cells were cultured 
under different conditions including 2D, 3D, static and dynamic flow and 
flow/pressure. In addition, to better understand the underlying molecular 
mechanisms of the observed alterations in cell growth, the expression of a 
range of markers was also evaluated.  
4.1.1. Cellular viability in 3D cell culture compared with 
conventional 2D cell culture 
 
The first part of this project involved culturing cancer cells in a 3D system, 
leading to the key question: does 3D culture alter cell proliferation and 
viability? To address this fundamental question, researchers have conducted 
diverse projects using various 3D culture methods and cell types. In this 
project, cell viability, an indicator of cell proliferation/growth was evaluated by 
assessing the metabolic activity of breast cancer cells grown in 2D monolayers 
and in 3D as ACMs of 10% w/v collagen type-I. Amongst the diverse cell 
viability assays available to researchers, the Alamar blue assay was selected 
owing to the non-toxic properties of this reagent which has allowed the assay 
to be performed at different time points on the same cells. Unfortunately, the 
Alamar blue assay was not suited to the analysis of cancer cells grown as 3D 
spheroids due to lack of reproducibility caused by floating/unattached cells.  
Since different numbers of the cells were initially seeded in the 2D and 3D 




rather than the actual percentage cell viability at each time point.  MDA-MB231 
cells were grown for 14 days (data not shown) and SKBR3 were grown for 7 
days as a significant decrease in the viability of SKBR3 cells was observed at 
day 7. Reduced viability rates for MDA-MB231 and SKBR3 cells were 
observed over the 7-day period when the cells were grown in 3D ACM 
compared to 2D.  In the case of MDA-MB231 cells, there was a significant 
difference between day 1 and day 3 when cells were grown in 3D compared 
to 2D, P<0.05. Although the (rate of) increase in cell viability was reduced in 
both culture conditions between days 3 and 7 a significantly lower rate was 
observed in 3D compared to 2D. The viability of SKBR3 cells increased 
approximately with a similar rate between day 1 and day 3 and continued to 
increase slightly on day 7 in 2D while a significant reduction was observed in 
the 3D culture (P<0.05). To assess whether the observed changes in cell 
viability, as measured using the Alamar blue assay, were due to an alteration 
in the proliferation rate of the cells, their metabolic activity and cell death 
(particularly apoptosis) was determined by measurement of the expression 
levels of markers of these processes using qRT-PCR.   
Ki67 is a proliferation marker associated with dividing cells, its expression 
varies in different phases of the cell cycle, but it is not detected while cells are 
in cell cycle arrest; G0 (Juríková et al., 2016).  MDA-MB231 and SKBR3 cells 
exhibited reduced expression levels of Ki67 when they were cultured in the 3D 
ACM compared to 2D monolayer cultures. These results were consistent with 
the results of the Alamar blue cell viability assay and suggest that growing the 
cells in collagen type-I may exhibit a decrease in cell division and, therefore, 
cell proliferation. However, when the cells were cultured in the ultra-low 
attachment plates and allowed to form spheroids a significant increase in the 
Ki67 expression level was observed compared with 2D cell culture (P<0.05). 
This may be associated with increased cell-cell interactions, a feature of 
spheroid formation. The increase in Ki67 expression levels in SKBR3 might be 
associated with the HER2 positivity of this cell line as Ki67 expression has 
previously been shown to be elevated in HER2 enriched cells compared to the 




of the levels of other cell-cycle-specific antigens including proliferating cell 
nuclear antigen (PCNA), and mini-chromosome maintenance (MCM) proteins, 
may help to further elucidate the molecular alterations involved in tumour cell 
growth and proliferation that occur when cells are cultured in 3D ACM. 
To further understand the behaviour of cells grown in 3D ACM the expression 
levels of genes coding for proteins involved in intrinsic and extrinsic apoptosis 
pathways were analysed. The pro-apoptotic markers caspase -3 and caspase 
-9 were expressed in the cancer cells at approximately the same level 
irrespective of whether cells were grown in 3D or in 2D cultures. The only 
exception was the significantly decreased expression-levels of caspase -3 
observed when SKBR3 cells cultured in 3D.  The expression-levels of the anti-
apoptosis marker BCL-2 of both cell lines was elevated when the cells were 
grown in 3D (ACM) compared to 2D. Taken together, the expression levels of 
BCL-2/caspase -3 and -9 suggest that the induction of apoptosis may not be 
the underlying mechanism associated with the reduction in cell viability 
described above. Analysis of a larger panel of genes and proteins involved in 
apoptotic processes in conjunction with other assays, for example annexin V 
and caspase 3/7 activity assays would serve to more fully understand the 
changes in cancer cell behaviour when grown in 3D.  
A further consideration when evaluating the data from the Alamar blue assays 
is that reduced cellular viability in the collagen scaffolds (ACMs) may result 
from a decrease in concentration of the Alamar blue reagent (dilution effect) 
when applied to the collagen matrix, and/or differential uptake of Alamar blue 
dye by cells which have formed clusters within the collagen. 
Previous studies using cancer cell lines have shown that cell proliferation rates 
depend on both the cell type and the ‘matrix’ supporting cell growth. In a study 
of endometrial cancer cell lines, RL95-2, KLE, EN-1078D, Chitcholtan et al 
(2013) reported a significant decrease in cell proliferation of cells cultured in 
reconstituted basement membrane (rBM) compared to 2D culture. Similarly, 
in another study, a panel of colorectal cancer cells including SW-480, HT-29, 
DLD-1, LOVO, CACO-2, COLO-205 and COLO-206F were grown in Matrigel 




proliferation, quantified by 5-bromo-2′-deoxyuridine, compared to the cells 
grown in 2D monolayers (Luca et al., 2013). Conversely, JIMT1 breast cancer 
cells exhibited a higher proliferation rate when cultured in Matrigel but slower 
growth in a synthetic, polyHEMA 3D scaffold compared with 2D culture 
(Hongisto et al., 2013). The viability of C4-2B prostate cancer cells grown in 
3D hyaluronic acid hydrogels was not found to be significantly different 
compared to those cultured in 2D, in a report utilising Trypan blue staining to 
count the total cells and the dead cells (Gurski et al., 2009). In a recent study, 
the proliferation of glioma cells lines, U87, U251 and HS683, was evaluated 
by determining the number of cells within collagen scaffolds and 2D 
monolayers over a 10-day time course. They concluded that cell growth 
declined in 3D collagen scaffolds compared to 2D culture and qRT-PCR and 
Western blot analysis revealed that the expression of Ki67 in the glioma cells 
reduced when they were grown in collagen scaffolds, compared with the 2D 
monolayer system (Jia et al., 2018).  
In summary, the results presented here indicate that the growth rate of MDA-
MB231 and SKBR3 cells collagen type-I matrix compared to growth as con-
ventional 2D monolayers. This reduction in cell growth was associated with 
decreased metabolic activity and/or arrest of cells in the G0 phase of the cell 
cycle but not apoptosis and cell death.   
4.1.2. Cellular viability and colony morphologies of the cells 
grown in 3D culture and in the presence of fluid flow 
 
Biophysical cues from the tumour microenvironment include the stiffness of 
the ECM, interstitial fluid flow and pressure and these have been shown to 
have broad-reaching effects on cancer cells (Broders-Bondon et al., 2018). In 
this part of the study, there were two aims: 1) to investigate if the cells 
remained viable under the new 3D/dynamic system which was developed in 
this project and 2) to compare viability and proliferation of the cells grown in 




ACMs were maintained under different conditions: static, flow (150 µL/min) 
and flow/pressure (550 µL/min, ~19mmHg) and cell viability was measured 
using the Alamar blue assay as described above.  
Applying a flow of media over the cells cultured as 3D ACMs resulted in a 
lower cell viability at a flow rate of 550 µL/min and pressure of ~19mmHg 
compared to cells grown in equivalent but static conditions. After 7 days cell 
culture, the viability of MDA-MB231 cells was significantly reduced when 
grown under flow/pressure compared with static conditions.  However, 
between days 7 and 14 a similar (rate of) cell viability was observed, 
irrespective of the culture conditions. If this tumour model were to be used in 
drug cytotoxicity testing setting, cancer cells would need to be maintained in 
the flow model at least for 7 days prior to treatment in order to avoid 
misinterpretations of the results. 
The viability of MDA-MB231 cells exposed to a flow rate of 550 µL/min without 
the application of pressure was similar when compared with cells cultured 
under static conditions (Appendix 6). When a flow rate of 150 µL/min was 
applied over the ACMs of MDA-MB231 cells the viability was similar to that 
observed in flow/pressure (results not shown). These results indicate that 
applying pressure while using high flow rates, affects the cell viability in the 
same manner as a low flow rate.   
Although there have been several in vivo studies with tumour tissue derived 
samples and animal models of cancer in which fluid flow/pressure have been 
associated with tumour cell proliferation, invasion and metastasis (Leunig et 
al., 1992, Hofmann et al., 2006).  Only a few in vitro studies have demonstrated 
that cancer cell proliferation is altered in the presence of fluid flow or high 
interstitial fluid pressure. In an in vitro study conducted on SCC-4 and SCC-9 
human tongue squamous carcinoma cells, an increase in the extracellular 
pressure from 15 mm Hg to 30 mm Hg resulted in a significant elevation in cell 
proliferation and an alteration in expression levels of more than 1800 genes 
involved in invasion and metastasis (Yu et al., 2013).  In another report, 
increasing the hydrostatic pressure (20, 50, 100 mm Hg) applied to primary 




(MCF7 breast, H1299 lung), using an Opticell–HPA cell culture system 
showed the cancer cells to react differently with regards to their proliferation 
rate(s) (DiResta et al., 2005). 
The results obtained during this project concur with previous research in which 
it has been reported that the application of sheer stresses to human cancer 
cells , two osteosarcoma and two oral squamous carcinoma, resulted in G2/M 
arrest and a decrease in cellular differentiation; with the mad signalling 
pathway recognised as the underlying molecular mechanism (Chang et al., 
2008). It would be intriguing to determine if the smad signalling pathway is 
activated in the MD-MB231 cells grown in the 3D ACM system utilised in this 
study. 
In contrast to the observations with the MDA-MB321 cells, when SKBR3 cells 
were used for the preparation of ACMs and maintained under flow and 
pressure conditions their viability reduced between day 1 and 7 whilst cells 
maintained under static conditions exhibited a significant increase in cell 
viability. This is the first report in which SKBR3 cells have been cultured under 
flow and pressure conditions; it may be the case that breast cancer cells 
behave differently depending upon their subtype, when maintained in 3D and 
under fluid flow and pressure.   
An investigation aimed at elucidating molecular mechanisms underlying the 
changes in cell viability evaluated the mRNA expression levels of the 
proliferation marker Ki67 and apoptosis-related markers caspase -3, caspase 
-9 and BCL2. MDA-MB231 and SKBR3 cells exhibited a significant increase 
in the expression level of Ki67 when grown under flow/pressure compared to 
static conditions. This report is the first of its kind to consider the effect of fluid 
flow and pressure on the Ki67 expression level in human cancer cells. The 
only previous report indicating an association between IFP and Ki67 found that 
lowering the IFP for at least 6 h significantly suppressed Ki67 expression in an 
epidermoid vulva carcinoma and lung carcinoma tumours of mice (Hofmann 
et al., 2007). It has been reported, however, that mechanical signals control 




with transcriptional enhanced associate domain (TEAD) is associated with 
increased cellular proliferation (Aragona et al., 2013). 
To further understand the behaviour of cells maintained in a microenvironment 
incorporating fluid flow and pressure, the expression levels of key genes 
involved in intrinsic and extrinsic apoptosis pathways were analysed. In these 
experiments caspase -9 expression levels were significantly increased in 
MDA-MB231 cells grown under flow and pressure, while caspase -3 and BCL2 
expression levels were decreased (non-significant) compared with the static 
3D cell culture conditions. However, in the case of the SKBR3 cells, significant 
increase in expression levels of either caspase -3 or caspase -9 were 
observed.  This is the first time that the effect of flow/pressure on the 
expression of apoptotic markers of cancer cells has been reported.  
Microscopic analysis revealed that the cancer cells form colonies when they 
are maintained in 3D conditions - a feature common to cells cultured under 
both static and flow conditions as ACMs. MDA-MB231 cells grew in regular-
shaped colonies in static conditions but under flow/pressure they displayed a 
‘grape-like’ morphology. In contrast, SKBR-3 cells exhibited a ‘grape-like’ 
morphology irrespective of the condition: static or flow/pressure. The types of 
colonies formed when breast cancers are grown in 3D has been the subject of 
a number of studies. The morphology of colonies of a large panel of breast 
cancer cell lines grown in 3D Matrigel, alongside their gene expression profiles 
was studied. They classified the morphology into four categories; mass, round, 
stellate and grape-like. The gene expression pattern of the cells was strongly 
associated with colony morphology. However, it was reported that MDA-
MB231 cells exhibited a stellate morphology and SKBR3 cells a grape-like 
morphology (Kenny et al., 2007). Comparing the results of this study with theirs 
it can be concluded that: 1) a specific cancer cell line can adopt different colony 
morphologies in biochemically or biophysically different microenvironments 
and 2) changes in the gene expression profile of the cells grown under 
flow/pressure may cause the changes in colony morphology. 
In summary, the growth rate of MDA-MB231 and SKBR-3 cells was reduced 




remained in static conditions. This reduction in cell growth was associated with 
reduced metabolic activity and increased apoptosis and was not associated 
with proliferative activity.  
4.2. Epithelial mesenchymal transition (EMT) of breast 
cancer cells grown under different conditions 
 
EMT is a process which occurs during tumour cell invasion and intravasation 
and the identification of factors that can trigger and sustain EMT is an 
important aim. EMT-related signalling pathways play an important role in 
epithelial-mesenchymal switching. Signalling pathways altered during EMT 
include TGF-β, Wnt/β-catenin and NF-κB. Transcription factors, for example 
STAT3 and snail, slug, Nanog, ZEB1 (Guaita et al., 2002a)  and microRNAs 
have also been implicated in this process (Ren et al., 2017). Factors in the 
tumour microenvironment have been shown to induce EMT in epithelial cancer 
cells leading to cellular invasion (and metastasis) (Yang et al., 2018). 
In this project, the effect of biochemical and biomechanical components of the 
tumour microenvironment on the expression of EMT-associated markers was 
investigated. 
4.2.1. EMT of breast cancer cells maintained in 3D cell 
cultures compared with conventional 2D cell culture 
 
In this part of the study the aim was to investigate whether growing MDA-
MB231 cells in 3D dense collagen type-I or in spheroids, rather than 
conventional 2D culture, would alter expression levels of mesenchymal 
markers. SKBR3 cells exhibited extremely low expression levels of vimentin, 
snail, N-cadherin, MMP14 and cadherin 11 when grown in either in 2D and 3D 




Relative quantification of the EMT markers vimentin, MMP14, snail and 
cadherin-11 was performed using qRT-PCR; an increase in the expression 
levels of these markers was observed when the cells were cultured in 3D as 
either ACM or spheroids. The exception was cadherin-11 expression-levels 
which were observed to decrease when MDA-MB231 cells were cultured in 
3D as ACM in type-I collagen.  
Vimentin is an important marker of EMT but a significant increase in the 
expression of this marker in most cells cultured in 3D compared with those in 
2D has not been reported. Further analysis of vimentin levels was undertaken 
by separation of proteins extracted from cells grown in both 2D and 3D by 
SDS-PAGE followed by Western blotting and by immunofluorescent, confocal, 
microscopy. MDA-MB231 cells grown in 2D and in 3D as ACM in collagen 
type-I did not exhibit a significant difference in overall levels of the vimentin 
protein. The Western blot analysis utilised a primary anti-vimentin antibody 
(D21H3, Cell Signalling Technology) raised against both the phosphorylated 
and non-phosphorylated forms of vimentin, accordingly, 2 bands were 
observed on the Western blots and whilst vimentin mRNA levels in 2D and 3D 
culture were not different, more of the vimentin filaments appeared 
phosphorylated when the cancer cells were grown in 3D as ACM.  
In contrast to the results obtained in this study, others have shown vimentin 
expression-levels to be increased when mammary epithelial cells were 
cultured in 3D collagen scaffolds or as spheroids. For example, the growth of 
the normal mammary epithelial cell line MCF 10A in 1-1.5 mg/mL collagen was 
associated with upregulation of vimentin gene-expression (Decarlo et al., 
2015). Another study utilising immunohistochemical methodology reported a 
significant elevation in vimentin levels when MCF7 cells were grown in 
spheroids compared to 2D culture (Herheliuk et al., 2016). Upregulation of the 
gene-expression and protein levels of vimentin were also reported when 
glioma cells were grown on collagen scaffolds with larger pore sizes (Jia et al., 
2018). Colorectal cancer cells HT29 and HTC116 were also cultured in the 
same collagen scaffold as the ACM used in this study. Western blot analysis 




the ACM compared with 2D cell culture (Magdeldin et al., 2017). It should be 
noted that HT29, HTC116, MCF7, MCF-10A and glioma cells do not express 
high levels of vimentin in 2D cell culture in contrast to MDA-MB231 cells which 
constitutively express vimentin. The results obtained in this study, therefore, 
suggest that when cells already express relatively high levels of vimentin, 
those levels do not alter when the cells are grown in 3D but rather the 
phosphorylation status of vimentin may be affected by the culture conditions.  
 MMP14 is a membrane-type matrix metalloproteinase (synonym MT1-MMP) 
which paves the path for cancer cell migration by cleavage of ECM 
macromolecules including collagen type-I, type-II, type-III, laminin-1, laminin-
5, fibronectin and vitronectin (Itoh, 2006).  MMP14 expression-levels were 
increased significantly when MDA-MB231 cells were grown in 3D as either 
ACMs or spheroids, compared with 2D culture. These results suggest that 
MMP14 expression levels in MDA-MB231 cells is affected by the 3D 
microenvironment irrespective of the presence of macromolecules associated 
with the ECM, the significance of this paradoxical finding remains unclear. 
Currently there are few reports concerned with the effect of 3D culture on the 
levels of MMP14 in cancer cells, although a recent study showed a significant 
increase in MMP14 expression levels in human mammary fibroblasts grown in 
3D collagen scaffolds compared to those grown in 2D (Sung et al., 2013).  
As detailed above, signalling pathways and transcription factors are involved 
in EMT. Amongst the transcription factors activated, snail has emerged factor 
as an important modulator of EMT, principally via its inhibitory effect on E-
cadherin levels (Guaita et al., 2002b). However, snail also controls other 
factors that are involved in cancer cell survival and invasion. For example, 
snail has been shown to regulate the glycolytic switch (Warburg effect) 
repressing levels of fructose-1,6-biphosphatase (FBP1) in basal type breast 
cancer cells (Dong et al., 2013). This in turn may lead to increased production 
of reactive oxygen species (ROS) with genotoxic effects (Wang et al., 2013). 
In addition to modulating soluble factors of the tumour microenvironment which 
trigger signalling pathways involved in snail activation, ECM molecules, for 




has shown that 3D culture of ovarian cancer cells on collagen type-I scaffolds 
induced expression of snail and slug through co-activation of TGFβ and Wnt 
signalling pathways (Liu et al., 2018). Another study revealed that the growth 
of pancreatic ductal adenocarcinoma cells in 3D collagen gels induced snail 
expression. The same study reported that TGF-β type-I receptor and its 
downstream effector molecules, smad3 and smad4, were essential for 
induction of snail by collagen (Shields et al., 2011). Furthermore, snail 
expression-levels have emerged as important in the lymph node metastasis of 
MDA-MB-231 cells (Olmeda et al., 2007). However, to date, little is known 
about the effect of the collagen type-I matrix in the expression of snail in MDA-
MB231 cells. In this study, MDA-MB231 cells were grown on ultra-low 
attachment surfaces or were embedded in collagen type-I (ACM) - a significant 
increase in snail mRNA expression-levels was observed in cells cultured in 3D 
(as ACMs and spheroids) compared with cells grown in 2D monolayers - 
suggestive that stimulating factors other than collagen may exist in the 3D 
microenvironment of tumour cells which induce snail activation. These results 
concur with previous studies utilising other cancer cell lines (Shields et al., 
2011, Carey et al., 2017, Liu et al., 2018). 
The final EMT related marker evaluated in this study was cadherin-11. 
Cadherin 'switching' occurs during EMT, a phenomenon described during 
human embryonic development and also during tumour invasion and 
metastasis. This 'switching' results in weaker homotypic cadherin interactions 
and consequently facilitates cell migration and invasion (Theveneau and 
Mayor, 2012). Higher cadherin-11 gene expression-levels have been reported 
for cancer cell lines derived from bone and this has led researchers to 
investigate whether there is a correlation between upregulation of cadherin-11 
in certain cancers including some types of prostate and breast cancers, and 
bone metastases. It has been reported that MDA-MB231 cells from secondary 
tumours in bone express higher levels of cadherin-11 compared to MDA-
MB231 with those metastatic to the brain. They also demonstrated that MDA-
MB231 cells re-expressing cadherin-11 are more prone to metastasise to bone 




cadherin-11 gave rise to a more invasive and motile phenotype compared to 
parental cells although they remained less motile than cells transfected with 
N- cadherin (Nieman et al., 1999). In this study, initially, qRT-PCR analysis 
was performed to evaluate the effect of cellular growth in the 3D 
microenvironment (collagen and spheroid) on mRNA expression-level of E 
and N-cadherin and cadherin 11. The results were consistent with those of 
Nieman et al. (1999): MDA-MB231 cells did not express E-cadherin and N-
cadherin (results not shown). Therefore, cadherin-11 expression of the cells 
grown in 3D was measured relative to those grown in 2D. The results showed 
that cadherin-11 mRNA expression decreased significantly in the cells grown 
in 3D scaffold while it increased significantly in the cells grown in the ultra-low 
attachment plates (spheroids). This observation suggests that MDA-MB231 
cells downregulate CDH11 gene upon exposure to collagen type-I, and that 
floating and unanchored MDA-MB231 cells express higher levels of cadherin-
11 mRNA compared to when they are attached to the surface of flask in 
conventional 2D culture method.  
 
4.2.2. EMT of 3D cell cultures in the presence of fluid flow 
 
To date, little research has been conducted on the impact of fluid flow and 
pressure on the induction of EMT in cancer cells. In this part of the project, the 
aim was to investigate how mechanical stress generated from interstitial fluid 
flow and pressure may interact with biochemical signals arising from ECM to 
induce EMT in solid tumours. MDA-MB231 cells grown as ACMs were 
maintained under static, flow (150 µL/min) and flow/pressure (550 µL/min, ~19 
mmHg) for two weeks. The mRNA expression levels of vimentin, snail and 
MMP14 in flow and flow/pressure was measured relative to the levels when 
cells were grown in static conditions. MDA-MB231 cells exhibited increased 
levels of vimentin, MMP14 and snail in the presence of fluid flow of 150 µL/min 




flow/pressure (550 µL/min, ~19 mmHg) conditions, only the MMP14 mRNA 
expression-levels increased significantly, while vimentin expression-levels 
significantly decreased, and snail expression-levels remained unchanged. 
Further analysis of vimentin levels was undertaken by Western blotting and 
immunofluorescent confocal microscopy. The MDA-MB231 cells grown in 3D 
collagen as ACMs under flow/pressure exhibited a significant decrease protein 
levels of vimentin compared to those grown in static conditions. Images 
obtained following immunostaining of the MDA-MB231 cells cultured in static 
and flow/pressure for 2 weeks showed reduced levels of vimentin protein in 
the cell aggregates at the edges of ACMs, where the cells invade to the 
surrounding stroma, when maintained under flow/pressure compared to their 
counterparts grown under static conditions. The increased vimentin mRNA 
expression-levels when ACMs were maintained under lower flow (150 µL/min) 
and pressure (~ 1 mmHg) may reflect increased levels, or ‘pockets’, of 
hypoxia, this may be evaluated by assessment of the hypoxia-inducible factor 
α (HIF-1α). HIF-1α has been shown to be involved in induction of EMT in 
cancer cells. Increased levels of MMP14 mRNA expression in flow and 
flow/pressure suggest that matrix remodelling, an essential factor for cellular 
invasion, is induced in the presence of flow and pressure. Overall, when MDA-
MB231 cells were cultured in 3D, irrespective of the conditions (static, flow and 
flow/pressure) increased expression-levels of vimentin, MMP14 and snail 
were observed, compared to cells maintained as 2D monolayers. The only 
exception was the reduction of vimentin mRNA expression levels of cells 
cultured in the flow/pressure system, discussed above. These results indicate 
that addition of complexity to the cell culture system perturbs expression-levels 
of genes involved in EMT. 
This is the first time the effect of fluid flow and pressure on the expression of 
EMT-associated genes of breast cancer cells grown in a dense collagen matrix 
has been reported. Other studies have investigated the impact of 
microenvironment on breast and ovarian cancer cells behaviour using different 
types of 3D engineered tumour models and flow systems. For example, it has 




EMT markers in MDA -MB231 cells embedded in 4 mg/mL collagen type-I. 3D 
cultures accommodated within chambers of PDMS were subjected to a 
hydrostatic pressure gradient between the core and the tip of cell aggregates 
in a model incorporating hypotension (Ptip>Pbase), hypertension (Ptip<Pbase) and 
control pressure (Ptip=Pbase) conditions generated by changing the height of 
the cell growth medium in the reservoirs connected to either sides of the 
channel. Hypotensive conditions promoted cellular invasion and vimentin/snail 
expression-levels were significantly increased compared to the other IFP 
profiles; epithelial markers (E-cadherin and keratin-8) were also upregulated 
under hypotension (Piotrowski-Daspit et al., 2016).  Rizvi et al. have 
maintained the ovarian cancer cell line OVCAR5 in a Matrigel-containing 
microfluidic system under continuous flow (2.0 µL/min) for 7 days: E-cadherin 
levels were down-regulated whilst vimentin and EGFR expression levels were 
upregulated under flow conditions compared to static 3D cell culture (Rizvi et 
al., 2013). Although the flow rate, pressure, ECM (both material and density) 
and the flow generating system used in our project were different from the 
previous studies, they all highlight the substantial roles of fluid dynamics in 
regulating EMT and which cells encounter under pathological and/ or 
physiological conditions.  
4.3. The effect of cell culture conditions on HIF-1α 
expression levels in breast cancer 
 
Since one of the objectives of this study was to develop a tumour model for 
drug discovery purposes and since increased amounts of HIF-1α have been 
associated with drug resistance mechanisms, the effect of different culture 
conditions on the expression of HIF-1α in MDA-MB231 and SKBR3 cells was 




4.3.1. HIF-1α expression of breast cancer cells in 3D cell 
culture 
The effect of different 3D culture systems (ACM and spheroids) on HIF-1α 
expression was assessed. A slight increase in HIF-1α mRNA expression-
levels was observed when MDA-MB231 cells were cultured in collagen 
scaffolds compared to 2D culture, whereas a significant increase in HIF-1α 
was observed in cells grown on the ultra-low attachment plates (spheroids). 
However, in the case of SKBR3 cells, HIF-1α expression was significantly 
elevated in both types of 3D culture (ACMs and spheroids), although there 
was a greater elevation in spheroids than in ACMs compared to 2D culture. 
These results suggest 1) the 3D collagen model (ACM) was not associated 
with the generation of hypoxic conditions for MDA-MB231 cells, 2) MDA-
MB231 cells are less sensitive to oxygen-depletion when they are grown in the 
dense collagen scaffold compared to SKBR3 cells; 3) the cancer cells grown 
in the spheroid format are exposed to a lower oxygen gradient in the centre of 
the spheroid which affects the general amount of HIF-1α expression in all cells 
and/or 4) HIF-1α may be associated with the upregulation of the EMT markers 
including snail, MMP14 and cadherin 11 in the 3D spheroid system. Previous 
studies have reported an association between hypoxia and expression of EMT 
markers in tumour cells. For example, it has been demonstrated that hypoxia-
stabilised HIF-1α induces EMT through enhancing snail transcription in 
hepatocellular carcinoma cells (Zhang et al., 2013). It has also been reported 
that hypoxic conditions lead to an increase in the levels of HIF‑1α, N‑cadherin 
and vimentin, but repressed the expression of E‑cadherin and cytokeratin in 
pancreatic cancer cells (Zhu and Zhao, 2017).  
4.3.2. HIF-1α expression of 3D cell cultures in the presence of 
fluid flow 
 
Increased levels of IFP and hypoxia are a feature of the tumour 




metastasis to local or distant sites (Finger and Giaccia, 2010). However, 
associations between tumour IFP and hypoxia have rarely been studied. In a 
study on human melanoma xenografts, tumours with high IFP (IFP >20 mm 
Hg) exhibited higher central hypoxic fraction compared to those with low IFP 
(Rofstad et al., 2014). The work reported in this thesis was concerned with the 
effect of fluid flow and pressure on HIF-1α expression-levels in tumour cells 
grown in 3D scaffolds (ACMs). HIF-1α mRNA expression was assessed to 
also understand the molecular alterations underlying induction of EMT (in 
MDA-MB231) and HER2 expression (in SKBR3) as well as drug resistance. 
The HIF-1α mRNA expression-levels were increased significantly in both cell 
lines in the presence of flow of 150 µL/min whilst, surprisingly, in the 
flow/pressure conditions (500 µL/min, ~19 mmHg) expression-levels remained 
nearly unchanged. These results suggest that lower flow rates generate a 
hypoxic condition in the bioreactor chamber while higher flow rate and 
pressure do not. Although the induction of hypoxia should be confirmed by 
other techniques, for example measurement of oxygen pressure inside the 
flow chamber and staining the cells with pimonidazole, (Varia et al., 1998), the 
results found during this study demonstrate the importance of assessing the 
hypoxia status of closed bioreactors and microfluidic systems used for the 
study of cancer cell behaviour and drug responsiveness under more 
physiologically relevant conditions. 
4.4. The effect of culture conditions on HER2 expression of 
SKBR3 cells 
 
HER2 overexpression has been reported in many types of malignancies 
particularly in breast and gastric cancers. HER2 overexpression occurs in 15-
20% of all breast cancer cases and is associated with poor prognosis and 
metastatic disease. Therefore, several HER2-targeting agents have been 
identified and established, including; Trastuzumab, Pertuzumab and Lapatinib 
(Nahta et al., 2004). Despite promising initial outcomes of these therapeutic 




the main complication in the clinic. Hence, further physiologically relevant in 
vitro tumour models are required to identify microenvironmental cues relevant 
to the drug discovery process.  Previous studies have shown that response to 
HER2 targeting drugs including Trastuzumab and Pertuzumab is highly 
dependent on whether cells are grown in 2D or 3D culture systems. For 
example, SKBR3 cells grown as 3D spheroids on Matrigel appeared to be 
more resistant to trastuzumab compared to those grown in a 2D monolayer 
system (Weigelt et al., 2010). It has been shown that HER2 overexpressing 
breast cancer cells stabilise HIF1α protein through PI3K and AKT pathway in 
nonhypoxic conditions (Laughner et al., 2001). Hence, in this study the HER2 
and HIF1α expression-levels of SKBR3 cancer cells cultured in 3D formats 
were compared with those grown in 2D monolayers.  
4.4.1.  HER2 expression of breast cancer cells in 3D cell 
culture 
 
In this study, we compared HER2 expression (at mRNA and protein level) for 
SKBR3 cells cultured in our 3D collagen engineered system (ACM) and 
spheroids relative to cells grown in the conventional 2D monolayer. A 
significant increase in HER2 mRNA expression level was observe for cells 
grown in 3D collagen and spheroids compared to 2D monolayers. The 
Western blot analysis showed a slight increase in the HER2 protein level of 
cells grown in 3D collagen (ACM) compared to those cultured in 2D. Similarly, 
(qualitative) analysis of confocal images also showed a slight increase in 
HER2 protein levels when SKBR3 cells were cultured in ACM compared to 
those grown in 2D monolayers. The results suggest that HER2 expression 
increases when the epithelial cancer cells aggregate spontaneously in an 
anchorage-independent manner without the addition of exogenous ECM. In 
turn, the increased cell-cell interactions during spheroid formation may trigger 
signals which induce HER2 expression. No alteration in total amounts of HER2 
protein levels was reported when SKBR3 cells were grown on polyHEMA 




phosphorylation of HER2 in 3D spheroids compared to 2D culture (Pickl and 
Ries, 2009). This may indicate that if our 3D model is going to be used in the 
future, one should consider the possible changes in the expression of HER2. 
Also, it may indicate that the necessity of considering ECM when Trastuzumab 
dosage and IC50 values are assessed in the drug discovery processes.  
 
HER2 expression of 3D cell cultures in the presence of fluid 
flow 
 
The analysis of HER2 levels is a diagnostic and prognostic tool used during 
the clinical management of breast cancer patients. HER2 levels are used to 
determine those patients likely to benefit from Trastuzumab (Herceptin) 
therapy. Targeted therapy using Trastuzumab (Herceptin) has been a gold 
standard therapy for treatment of HER2 positive breast cancer patients.  With 
the application of new in vitro tumour models, implementing mechanical 
aspects of the tumour microenvironment in drug discovery and personalised 
therapy, it is important to understand whether the target molecules and/or 
biomarkers themselves undergo conformational and/or transcriptional 
changes in according to the different microenvironments. Since the tumour 
model and flow system designed in this study might, in the future, be used to 
assess SKBR3 response to Trastuzumab an investigation into whether HER2 
levels are altered when cells are grown as ACM was undertaken. A further 
objective was to determine if an increase in the fluid flow and pressure affected 
the expression of HER2 in HER2 enriched breast cancer cells. This has been 
studied for the first time in this project and no previous research has been 
conducted in this area. The results showed that HER2 gene expression-levels 
increased significantly (P<0.05) when the cells were grown under flow + 
pressure compared to static conditions. HER2 levels were also investigated 
using protein and cells using confocal microscopy. Qualitative analysis of the 
microscopy images showed no increase in HER2 of cells cultured in flow + 




suggest that if the in vitro tumour model and Quasi Vivo system used in this 
project were to be employed as a platform for testing HER2 targeting 
therapeutic agents, changes in the level of HER2 expression should be 
considered prior to treatment. The results showed that increased fluid flow and 
pressure in the tumour microenvironment is associated with an increase in the 
HER2 expression in breast cancer cells. 
4.5. Efficacy of doxorubicin under different culture 
conditions 
 
The five-year survival following breast cancer has increased from 
approximately 30% in the 1970s to 80% in 2016 (Cancer research UK, 2017). 
This has been a result of improved diagnosis and the development of many 
cancer treatments including chemotherapy, immunotherapy, hormone therapy 
and radiotherapy. Nevertheless, cancer remains a leading cause of death 
worldwide and there is a need to understand the treatment responses for 
individual cancer patients. It is also not uncommon for anti-cancer drugs which 
have demonstrated promise during the development phase in pre-clinical 
research to fail during the clinical trial phase. This failure, known as the attrition 
rate, is in part due to the intrinsic complexity and heterogeneity of tumours; 
features that are often difficult to recapitulate during the drug discovery phase.  
Since the 1970s, cancer cells have been cultured on 2D surfaces as 
monolayer cultures while biochemical and physical cues found in the TME 
have often been overlooked. The interaction between tumour cells and the 
microenvironment triggers reciprocal alterations in their structures and the 
physiological functions that support tumour growth and invasion, and the TME 
has been shown to affect cancer cell sensitivity and resistance to treatments 
(Giancotti and Ruoslahti, 1999).  
Conventional monolayer cultures (2D) are simplistic models for testing 
therapeutic drugs failing to reflect key aspects of tissue architecture. In 2D 




cells, adhering to a plastic or a glass surface, this results in a default apical-
basal polarity and cell shape which can alter cell function (Baker and Chen, 
2012), in contrast, when cells are cultured in 3D they have a greater surface 
area for cell-cell attachments and have been shown to have more contacts 
with neighbouring cells.  
When cancer cells are grown as 2D monolayers they are exposed to equal 
levels of oxygen, nutrients, waste products and therapeutic agents, whilst in 
vivo, a cancer cell mass would be exposed to the gradients of these 
components across the tumour, a phenomenon which can be recapitulated in 
3D cell culture models (Lin and Chang, 2008). 
In this project the effect of different microenvironmental conditions on cancer 
cell viability following treatment of the cells with chemotherapeutic drugs was 
assessed. Doxorubicin was chosen as it is used as a combination therapy for 
breast cancer treatment. MDA-M231 and SKBR3 cells were grown in the 
different culture conditions (2D, 3D static and dynamic) and were treated with 
doxorubicin hydrochloride. After 48 hours treatment, the viability of the cells 
was measured using the Alamar blue assay.  
4.5.1. Efficacy of doxorubicin when breast cancer cells are 
cultured in 3D 
 
Initially, the cytotoxic effect of different concentrations of doxorubicin on cells 
grown in 2D and 3D cultures was investigated. This experiment was also 
performed to optimise the concentration of doxorubicin to be used in 
subsequent experiments. In general, the Alamar blue assay results showed 
that cells cultured in 3D were less responsive to doxorubicin treatment 
compared to 2D, this was significant at the concentrations of 1 µM and 5 µM 
for cells treated in 3D compared 2D culture (P<0.01), figure 18. The increased 
resistance of cancer cells to the chemotherapeutic agent when they were 
grown in 3D compared with 2D may be attributed to limited drug diffusion 




doxorubicin hydrochloride is 579.98 kDa which is greater than nutrients and/or 
Resazurin, the main constituent in the Alamar blue reagent. In addition, as 
reported above (section 3.3), SKBR3 cells exhibited a significant increase in 
HIF-1α mRNA expression in the 3D ACM system compared to conventional 
2D cell culture. HIF-1α has been shown to be associated with induction of 
genes associated with cellular survival (Ziello et al., 2007). Therefore, reduced 
drug responsiveness in SKBR3 cells grown in 3D (ACM) may be associated 
with increased expression of HIF-1α. Furthermore, the increased level of 
antiapoptotic marker BCL2 in both cell lines grown in 3D (ACM) compared to 
2D may also be associated with increased resistance to Doxorubicin 
treatment.  
In the case of MDA-MB231 cells, elevation in the expression of EMT markers 
MMP14 and snail may also have contributed to the decreased sensitivity to 
doxorubicin in 3D compared to 2D culture. These results are consistent with 
previous studies in which cancer cells were treated with chemotherapeutic 
drugs in 2D and 3D culture conditions. For example, it has been reported that 
the viability of human epithelial ovarian cancer cells OV-MZ-6 grown as 3D 
spheroids was 50% greater than the viability of 2D cell monolayers following 
the same level of exposure to Paclitaxel (Loessner et al., 2010). Another study 
showed that immortalized human cervical cells, HeLa, had lower toxic 
response to doxorubicin after 24h exposure when they were grown in collagen 
type-I compared to 2D monolayer culture (Casey et al., 2016). The sensitivity 
of colon cancer HT-119 cells to four standard anticancer drugs (melphalan, 5-
FU, oxaliplatin, and irinotecan) has been reported to be lower when the cells 
were grown in 3D culture compared to 2D monolayers (Karlsson et al., 2012). 
In this study, SKBR3 cells were found to be non-responsive to <1 µM 
doxorubicin when maintained as 2D cell culture whilst MDA-MB231 cells were 
sensitive to ≥0.1 µM. SKBR3 cells were, however, more sensitive to 
doxorubicin at concentrations of 5 µM and 10 µM compared to MDA-MB231 
cells treated with the same concentration. The greater sensitivity to 
doxorubicin may be attributable to the positive HER2 status of SKBR3 cells 




n=220 breast cancer patients with tumours >2.5 cm diameter, three cycles of 
doxorubicin was found to be more effective for patients with HER2 positive 
tumours than HER2 negative patients (Campiglio et al., 2003). Collectively, 
the results obtained here indicate that conventional 2D monolayer cell culture 
methods lack fundamental microenvironmental cues as determining factors for 
drug responsiveness.  
 
 
4.5.2. Efficacy of doxorubicin when breast cancer cells were 
cultured in the presence of fluid flow 
 
Over the last two decades there has been an interest in the potential effect of 
increased IFF and IFP on efficacy of different cancer therapeutics. It has been 
argued that elevated IFF and IFP may be associated with treatment failure 
particularly when therapeutic agents are delivered systemically (Heldin et al., 
2004). High molecular-weight drugs such as biological, immunotherapy and 
nanoparticles are transported and delivered via the circulatory system by 
moving through the interstitial space by convection (i.e. carried by streaming 
fluid) whereas small molecules (<1 kDa) mainly diffuse from areas with high 
concentrations to the area with low concentration (Rippe and Haraldsson, 
1994). Increased IFP in the centre of the tumour and the sharp drop in IFP at 
the edge generates a high-pressure gradient at the periphery of the tumour. 
However, many modelling data also suggest that there is uniform high 
pressure over the majority of the tumour mass. Either of these phenomena 
may contribute to reduced uptake of therapeutic agents by the tumour cells 
and a non-uniform distribution of drugs in the tumour mass (Welter and Rieger, 
2013). A further important factor is the observation that anti-cancer drugs may 
be sequestered by the tumour cells or may bind to molecules in the 
extracellular matrix, hindering drug penetration deep into the tumour (Berk et 




delivering therapeutic drugs such as chemotherapeutic agents into the centre 
of a tumour mass (Heldin et al., 2004). In another study, high IFP found to be 
associated with low diffusion of anti EpCAM MOC31 antibody into xenograft 
tumour models of HT29 colorectal cancer cells (Heine et al., 2012). Studies 
concerned with the role of IFP of tumours in the response of patients to cancer 
treatment have reported that decreasing IFP using Imatinib, an inhibitor of 
platelet-derived growth factor receptor, resulted in improved treatment 
response to chemotherapeutic drugs (Taxol and 5-FU) in mice bearing thyroid 
carcinoma tumours (Pietras et al., 2002).  
In this project the cytotoxic effects of doxorubicin on SKBR3 and MDA-MB231 
cells grown and treated under dynamic conditions was compared with its effect 
on cells treated under static conditions. The results showed a significant 
increase in the viability of the cells (survival) under dynamic conditions for both 
cell lines compared to static conditions. Sensitivity of MDA-MB321 cells to 
doxorubicin decreased significantly when cells were treated under 
flow/pressure or flow (150 µL/min) conditions compared to static condition. 
SKBR3 cells also exhibited significantly higher resistance to doxorubicin 
treatment under flow and pressure compared to static condition (P<0.05). The 
reduction of sensitivity to doxorubicin treatment in dynamic compared to the 
static conditions may be associated with various molecular events within the 
ECM or cancer cells themselves. For instance, flow and/or pressure may 
induce ECM matrix remodelling and alter collagen network deposition and/or 
stiffness resulting in stimulation of integrin signalling and cancer cell 
proliferation and survival (Paszek et al., 2005). 
Our findings are consistent with the results obtained in other studies. For 
example, MCF7 and MDA-MB231 cells exhibited much greater resistance to 
doxorubicin and paclitaxel when they were grown under flow compared to 
static conditions (Pradhan et al., 2018). In that study, the cancer cells 
encapsulated with BJ-5ta normal human foreskin immortalized fibroblasts 
within PEG-fibrinogen (PF) hydrogels and housed in a microfluidic chip and a 
continuous flow of (0.1 μL/min) was generated using syringe pump. 




prior to housing the cells and matrix inside the chamber to recapitulate 
vascular network surrounding the tumour. The 3D static condition contained 
the same components as the flow except for endothelial cells and dynamic 
flow (Pradhan et al., 2018). 
Overall, the results obtained in this study indicate 1) the necessity of 
incorporating other pathophysiological complexities into tumour models used 
in drug testing processes; 2) the importance of assessment of biophysical 
characteristics of the solid tumours before selecting the treatment regimen for 
a patient.   
4.6. Addition of fibroblasts to breast cancer cell cultures 
 
Fibroblasts are the main stromal cells in breast, prostate and pancreatic 
carcinoma (Alkasalias et al., 2018). During tumourigenesis, normal fibroblasts 
become activated and undergo a phenotypic modification and transform to 
cancer associated fibroblasts (CAFs). Although CAFs can originate from other 
types of cells including adipocytes, epithelial cells, endothelial cells (Zeisberg 
et al., 2007), bone marrow derived mesenchymal stem cells (Quante et al., 
2011), and hematopoietic stem cells, it has been shown that cancer cells 
induce the conversion of resident fibroblasts to CAFs by secreting cytokines.  
In turn, CAFs positively promote survival and proliferation of cancer cells by 
secreting growth factors and cytokines including CXCL12 (Orimo et al., 2005, 
Yu et al., 2014b), CCL7 (Jung et al., 2010), TGFβs (Zhuang et al., 2015), 
fibroblast growth factors (FGFs) (Bai et al., 2015), HGF (Tyan et al., 2011), 
periostin (Ratajczak-Wielgomas et al., 2016) and TN-C (O'Connell et al., 
2011). To date, the impact of fibroblasts on cancer cells has been studied 
either by various co-culture methods (2D and 3D) or by growing cancer cells 
on fibroblast conditioned medium.  In this study, normal fibroblasts were grown 
in collagen type-I (RAFT) and flow condition, while they were connected to 
cancer cells (ACMs) in a series set up in the Quasi Vivo system. This method 




This closed system allowed to mimic the paracrine signalling that occurs 
between cancer cells and fibroblasts. The aim was to investigate if normal 
breast-derived fibroblasts grown under flow conditions alter the expression of 
EMT related and proliferation-associated genes in the cancer cells. 
The initial qRT-PCR results for expression of EMT markers and Ki67 genes 
showed that mRNA expression levels of MMP14 and snail increased while 
vimentin and Ki67 remained unchanged and cadherin 11 decreased in MDA-
MB231 cell grown under flow in the presence of normal breast-derived 
fibroblasts. These findings suggest that normal fibroblasts may be converted 
to CAFs under flow condition and affect invasion of cancer cells by increasing 
the expression of matrix metalloproteinase.  
To investigate the effect of fibroblasts on invasion distance of cancer cells, 
fibroblasts were co-cultured with cancer cells in ACM, embedding fibroblasts 
in the stromal collagen surrounding the cancer cells. The initial images and 
qualitative analysis of invasion distances showed that MDA-MB231 cells 
invade over further distance when they are co-cultured with fibroblasts 
compared to those in the absence of fibroblasts. These findings suggest that 
normal fibroblasts increase cancer cell invasion to stroma. However, the 





Future perspectives  
 
In this project, a bioengineered tumour model was combined with a Quasi Vivo 
bioreactor system for the first time to produce a biomimetic breast tumour. The 
findings were encouraging, indicating that dynamic flow conditions modulate 
cancer cell behaviour and response to treatment. However, further 
investigations can be carried out in a number of different areas. Such future 
work might be considered in four broad areas: 
The first area would focus on further refinement of the bioengineered tumour 
model by addition of other biochemical components of tumour environment.  
The results indicated that dynamic flow conditions modulate cancer cell 
behaviour and response to treatment. However, apart from cancer cells, the 
biochemical phase of the tumour microenvironment is also affected by flow 
conditions. Therefore, addition of other biochemical components of the ECM 
including laminin, fibronectin and hyaluronic acid would serve to provide more 
complexity to the bioengineered 3D system and would better recapitulate the 
in vivo condition. In addition, to investigate the regulatory effects of stromal 
cells including fibroblasts (HDFs or CAFs) on inducing EMT and invasion of 
cancer cells in the presence or absence of flow and pressure, these cells can 
be added to the stromal collagen surrounding the cancer cells. Since 
immunotherapy is an emerging approach in cancer treatment, the immune 
cells including neutrophils, macrophages and lymphocytes could usefully be 
added to the stromal collagen to investigate the interplay between these cells 
and the cancer cells. Endothelial cells may also be added to stromal collagen 
to create a microvasculature network within the ACMs, enabling to study the 
interaction between endothelial cells and the cancer cells.  
The second phase would be to expand and validate the present tumour model 
using a larger panel of breast cancer cell lines and/or different types of cancer 
cells. Breast cancer subtypes are highly heterogenous and may behave 
differently in our bioengineered model and under flow condition(s). 




epithelial cells behave and respond to treatment in the model would also open 
new avenues for creating a physiologically relevant model for studying cell 
behaviour(s).  
The third area would concentrate on various applications of this in vitro tumour 
model in cancer research. Primary renal carcinoma cells have been grown in 
RAFT culture system successfully (Prof. Loizidou, unpublished data). Primary 
cancer cells isolated from breast cancer patients might be usefully grown in 
this model and under the flow conditions. This would allow for drug 
responsiveness of the tumour cells isolated from each patient to be tested in 
the biomimetic microenvironment which ultimately would facilitate patient 
stratification, currently incorporating in clinical trials. 
Another application would be using the Quasi Vivo circuit system to provide a 
co-culture system where the cancer cells grown in 3D culture in one chamber 
connect to the other chamber containing cells from other organs which are 
most likely to be the sites of distant metastases. This approach might help to 
elucidate mechanisms underlying metastasis and might offer potential in terms 
of prediction of the potential likely site for distant metastasis for patients. 
The final priority for future work would be to investigate the molecular 
mechanisms and signalling pathways as well as matrix remodelling which may 
be induced under the flow and pressure condition used in this study. For 
example, changes in collagen orientations might be studied using scanning 
electron microscopy. An investigation into how tissue stiffness and flow 
modulate penetrance and delivery of drugs through 3D volumes, nanoparticle-
conjugated drugs with imaging capacities can be used. Mathematical 
modelling concentrating on developing prediction algorithms based on the 
physical characteristics of the drugs and the environmental parameters would 






This study has provided evidence that cancer cells behave differently in 
response to changes in the tumour microenvironment.  Growing cancer cells 
in a more complex bioengineered tumour model containing components of 
tumour microenvironment including ECM and fluid flow and pressure resulted 
in a reduction of cell viability compared to conventional 2D culture. Molecular 
mechanisms underlying this reduction in cell viability include changes in 
proliferation and the apoptotic capacities of the cancer cells in the new 
microenvironment. The results indicated that biochemical and mechanical 
components of tumour microenvironment affect the expression of the genes 
involved in EMT of cancer cells. Growing breast cancer cells in a 3D format 
under flow conditions altered expression levels of genes related to hypoxia 
which might be due to differential distribution of oxygen in the more complex 
tumour model system developed during this project.  
A unique finding of this study has been the observation that when cells are 
cultured in 3D scaffolds, they adopt a different colony morphology under flow 
and pressure conditions compared to static conditions. The sensitivity of 
breast cancer cells to doxorubicin treatment decreased when the cells were 
maintained in 3D culture compared to 2D culture and in flow/pressure 
compared to static conditions.  
Collectively, the results obtained in this project indicate the substantial role of 
biochemical and mechanical cues of the tumour microenvironment on cancer 
cell behaviour and highlight the importance of incorporating complexity into in 
vitro tumour models used for studying cancer and used for preclinical phases 
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Chemicals used in this project 
 
 
Chemical Company and country 
Tris base Sigma Aldrich 
Glycine Sigma Aldrich 
Methanol VWR 
Ethanol VWR 
Formaldehyde 4% w/v Sigma 
Tween 20 Fisher Scientific 
Sodium Dodecyl Sulphate (SDS) Sigma 
30% Acrylamide/Bis Sigma 
HCl Thermofisher 
TEMED Sigma 
HEPES buffer Sigma 
NaOH Thermofisher 
Hanks Balanced Salt Solution 
(HBSS) 
Sigma 
Triton X-114 Sigma 
Glycerol PROLABO 
























RNA integrity test on 1% agarose gel (2D Vs 3D) 
 












Ki67 mRNA expression in static and flow/pressure conditions 
compared to 2D culture  
 















EMT markers mRNA expression in static and flow/pressure 
















Cell viability (static vs flow, 150 µL/min) 
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